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RESUMO 
A NADPH citocromo P450 oxidoredutase (CPR) é o fornecedor electrónico obrigatório 
para os citocromos P450 (CYPs) microssomais. Estes desempenham um papel central no 
metabolismo de hormonas esteróides, vitaminas, fármacos e outros xenobióticos. 
Demonstrou-se que a CPR existe num equilíbrio conformacional dinâmico, altamente 
dependente da força iónica, determinante para a sua função de transferência eletrónica 
(TE). A CPR transita entre uma conformação compacta (estado fechado) e conformações 
abertas (estado aberto). Admite-se que uma secção específica de um domínio funcional 
da CPR, conhecida como segmento hinge (“dobradiça”), desempenhe um papel 
importante na dinâmica e TE da CPR. 
O principal objetivo deste trabalho de Doutoramento foi estudar o papel de resíduos 
específicos da hinge no equilíbrio conformacional da CPR, o seu papel no efeito da força 
iónica na dinâmica aberto-fechado e na interacção com diversos parceiros redox 
estruturalmente diversos. Para tal, foram construídos oito mutantes, visando os resíduos 
da hinge G240, S243, I245 e R246, com o objetivo de modificar a flexibilidade e 
potenciais interações iónicas. Verificou-se o efeito destas mutações na CPR na forma 
solúvel ou membranar, medindo a redução da proteína solúvel citocromo c a várias 
concentrações de sal. Todos os mutantes foram capazes de reduzir o citocromo c ainda 
que com diferentes eficiências, no entanto, as taxas de redução máxima foram deslocadas 
para concentrações de sal menores. Os resultados levam-nos a admitir a hipótese de uma 
rede de pontes de hidrogénio em torno do resíduo R246, envolvido na dinâmica aberto-
fechado. Curiosamente, os efeitos das mutações, embora semelhantes, demonstraram 
diferenças entre formas solúveis e membranares da CPR. Os resultados demonstraram o 
aspecto crítico das propriedades eletrostáticas e de flexibilidade da hinge para a função 
de TE da CPR. 
Embora a utilização de um parceiro redox substituto, citocromo c, tenha sido informativo, 
a CPR pode funcionar de maneira diferente com os seus aceitadores naturais. Por 
conseguinte, foram selecionados três mutantes da CPR (S243P, I245P, R246A), e 
combinados com três CYPs representativos do metabolismo de fármacos, nomeadamente 
as isoformas 1A2, 2A6 ou 3A4. Diferentes abordagens experimentais foram empregues 
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para verificar o efeito dessas mutações na funcionalidade dos CYPs: capacidade de 
bioactivação de pré-carcinogénios, cinética enzimática, efeito da força iónica e 
competição do citocromo b5 (CYB5). As mutações na hinge influenciaram a bioactivação 
de pré-carcinógénios de um modo dependente da isoforma do CYP e até do substrato. Os 
desvios nos parâmetros cinéticos dos três CYPs quando combinado com cada enzima 
mutante, tendem a confirmar essa discrepância. Isto foi ainda confirmado pelos perfis de 
sal/actividade, específicos para cada CYP e mutante hinge. As experiências de 
competição CPR:CYB5 indicaram um papel menos importante da afinidade na dinâmica 
aberto-fechado. Juntos, os dados sugerem que a hinge é responsável pela existência de 
um agregado de diferentes conformações abertas, permitindo a interacção e TE com 
parceiros redox estruturalmente variados. 
Globalmente, este trabalho de doutoramento identificou resíduos-chave da hinge 
importantes na dinâmica e na função da CPR. Os dados obtidos suportam a existência de 
um mecanismo molecular subjacente que permite à CPR a TE para parceiros redox 
estruturalmente diversos, uma questão intrigante que estava pouco clara até agora. 
Palavras-chave: NADPH citocromo P450 oxidoredutase (CPR); citocromos P450 
(CYP); dinâmica proteica; transferência eletrónica (TE); interação proteína-proteína. 
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ABSTRACT 
NADPH cytochrome P450 oxidoreductase (CPR) is the obligatory electron supplier for 
all microsomal cytochrome P450s (CYPs). These play a central role in the metabolism of 
steroid hormones, vitamins, therapeutic drugs and other xenobiotics. CPR has been shown 
to exist in a dynamic conformational equilibrium, highly dependent on ionic strength 
conditions, determinant for its electron-transfer (ET) function. CPR transitions between 
a compact conformation (locked state) and open conformations (unlocked state). A 
specific section of one of CPR’s functional domains known as the hinge segment has been 
postulated to play a major role in CPR’s dynamics and ET. 
The main goal of this PhD-research was to study the role of specific residues of the hinge 
in the conformational equilibrium of CPR, their role in the ionic strength effect of the 
open-closed dynamics and in the interaction of CPR with structural diverse redox 
partners. For this purpose, eight mutants were constructed, targeting hinge residues G240, 
S243, I245 and R246, with the aim of modifying flexibility and potential ionic 
interactions. The effect of these CPR mutations were verified either in a soluble or in its 
membrane bound form, measuring the reduction of the soluble protein cytochrome c at 
various salt concentrations. All mutants were found capable of reducing cytochrome c yet 
with different efficiencies, however maximal reduction rates were shifted to lower salt 
concentration. Results lead us to hypothesize a hydrogen bond network around residue 
R246, involved in the open/closed dynamics. Interestingly, the effects of mutations, 
although similar, demonstrated specific differences between soluble and membrane-
bound CPR forms. Results demonstrated the critical aspect of electrostatic and flexibility 
properties of the hinge for CPR’s ET function. 
Although the use of the surrogate redox partner cytochrome c was informative, CPR may 
function differently with its natural acceptors. Therefore, three CPR hinge mutants were 
selected (S243P, I245P and R246A) and combined with three representative drug-
metabolizing CYPs, namely isoforms 1A2, 2A6 or 3A4. Different experimental 
approaches were employed, to verify the effect of these hinge mutations on CYP 
functionality: bioactivation capacity of pre-carcinogens, enzyme kinetic analysis, effect 
of ionic strength and cytochrome b5 (CYB5) competition. The hinge mutations influenced 
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the bioactivation of pre-carcinogens, which seemed CYP-isoform and even substrate 
dependent. The deviations of enzyme kinetic parameters of the three CYPs when 
combined with each of the mutants, tend to confirm this discrepancy. This was further 
confirmed by the CYP-isoform and hinge mutant specific salt/activity profiles. The 
CPR/CYB5 competition experiments indicated a less important role of affinity in the 
open/closed dynamics. Together data suggest that the hinge is responsible for the 
existence of a conformational aggregate of different open CPR conformers, enabling ET-
interaction with structurally varied redox partners. 
Overall, this PhD research has uncovered several key residues of the hinge in CPR’s 
protein dynamics and function. The obtained data seem to support an underlying 
molecular mechanism, permitting CPR’s ET to structurally diverse redox partners, an 
intriguing issue which has been unclear so far. 
Keywords: NADPH-cytochrome P450 reductase (CPR); microsomal cytochrome P450 
(CYP); protein dynamics; electron-transfer (ET); protein–protein interaction. 
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1.1 Biotransformation 
Humans are daily exposed to a wealth of chemicals, such as pharmaceuticals, cosmetics, 
dietary, environmental or occupational chemicals, designated as xenobiotics. This 
exposure, although often involuntary, may be chronic. These compounds may come into 
contact with the human body through a variety of routes, namely respiratory, cutaneous 
or oral. Once absorbed, the chemicals may exert a local effect and can then enter the 
systemic or portal circulation, being distributed to other tissues (Guengerich and 
MacDonald, 2007). 
Some of these compounds are lipophilic which facilitates absorption through the skin, 
lungs and gastrointestinal tract and makes elimination more difficult as they can more 
easily cross membranes, being reabsorbed and accumulating in the body. After absorption 
and distribution, the elimination of compounds usually depends on their conversion to 
hydrophilic molecules, with higher polarity and greater aqueous solubility, in a process 
called biotransformation or drug metabolism to facilitate its excretion in the urine, bile or 
feces, either by the action of the kidneys or liver (Parkinson and Ogilvie, 2008).  
Xenobiotics can exert a variety of effects on biological systems, which may be beneficial 
as most therapeutic drugs or may result in harmful effects. These effects are dependent 
on the physicochemical properties of the parent compounds and respective metabolites, 
determinant for their potential interaction with cellular targets. Biotransformation may 
result in the formation of chemically reactive metabolites (metabolic activation or 
bioactivation), capable of interacting with cellular molecules, which may lead to toxicity 
and genotoxicity (Parkinson and Ogilvie, 2008; Claesson et al., 2013; Pelkonen et al., 
2015).  
Biotransformation occurs in almost all tissues, but its main site of action is the liver and 
is mediated by several types of drug metabolizing enzymes (DMEs). These enzymes may 
be classified by the different types of chemical modifications they mediate (Zanger et al., 
2008). Phase I reactions involve the introduction or modification of a functional chemical 
group of the compound by oxidation,    hydrolysis or reduction, typically resulting in an 
increase of hydrophilicity of the compounds. Phase II type reactions involve the 
conjugation with endogenous polar cofactors, normally resulting in greater increase in 
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hydrophilicity. These conjugation reactions include glucoronidation and formation of 
Acyl-CoA thioesters, sulfonation, acetylation, methylation, phosphorylation, glutathione 
and amino acid conjugation (Xu et al., 2005; Parkinson et al., 2013). 
In Phase I metabolism, the CYP family is the major enzymatic system involved 
(Guengerich and Isin, 2008; Rendic and Guengerich, 2015). The remaining of Phase I 
metabolism is carried out by a variety of other contributing enzymes including flavin-
containing monooxygenases, NADPH:quinone oxidoreductase and several other, such as 
dehydrogenases, esterases and oxidases (Guengerich and Isin, 2008). Phase II metabolism 
is carried out by UDP-glucuronosyl transferases, epoxide hydrolases, sulfotransferases, 
N-acetyl transferases, gluthathione S-transferases and various methyltransferases 
(Jancova et al., 2010).  
Drug metabolism plays a major role in adverse drug reactions (ADRs). These concern 
harmful and undesired response to drugs in therapeutic doses and are in majority the result 
of bioactivation (Park et al., 2011). Individual susceptibility to chemical toxicity is largely 
dependent on genetic polymorphism of phase I and II enzymes, altering expression, 
structure or function of the enzymes. Many drugs known to cause ADRs are metabolized 
in processes catalyzed by polymorphic CYP (Johansson and Ingelman-Sundberg, 2011; 
Zhou et al., 2017; Ingelman-Sundberg et al., 2018; Lauschke and Ingelman-Sundberg, 
2018). The understanding of the role of genetic polymorphism and variation in CYP 
mediated biotransformation is therefore fundamental for the comprehension of inter-
individual differences in chemical exposure, adverse drug effects and toxicity in general. 
For example, individuals carrying the variant CYP2C9 alleles *2 and *3 have a significant 
reduction of warfarin clearance and are more susceptible to adverse bleeding events. 
Genotyping of CYP2C9 can predict warfarin dose and patients predisposed to unstable 
anticoagulation during initiation of therapy (Zanger et al., 2008; Johansson and Ingelman-
Sundberg, 2011; Zanger and Schwab, 2013). A detailed knowledge on the molecular 
mechanism of function of the CYP enzyme complex is desired to gather fundamental 
insights, to explain how genetic variation of protein factors of this enzyme complex may 
cause altered activities, and to rationalize their role in toxic responses in chemical 
exposure.  
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1.2 Cytochrome P450 
Mammalian CYP are a superfamily of monooxygenases heme-proteins (Guengerich et 
al., 2005 in Montellano). Of the 57 human CYPs identified, all are integral membrane-
bound proteins, with fifty located on the cytosolic side of the endoplasmic reticulum (ER) 
and the remaining seven on mitochondrial membranes (Table 1.1, Rendic and 
Guengerich, 2015). CYP or P450 was designated due to its rather unique spectral 
properties: an absorption band at approximately 450 nm in its reduced state and when 
complexed with CO (Omura and Sato, 1964a, 1964b). CYP are classified based on their 
amino acid sequence homology. With <40% of homology, CYPs belong to a different 
family and are identified by a number. With 40-55% homology, CYP are grouped in the 
same sub-family, which is identified by a letter. Within a sub-family of CYPs, individual 
isoforms are distinguished by a number (Nelson et al., 2004; Nelson et al., 2006).  
CYP enzymes are involved in the metabolism of drugs, carcinogens, pesticides but also 
of endogenous compounds such as steroids, fat-soluble vitamins, and many other types 
of chemicals (Guengerich et al., 2016). CYPs are versatile enzymes and capable of 
catalyzing a wealth of detoxification and biotransformation reactions with a multitude of 
different classes of substrates (Table 1.1). The broad substrate specificity of this enzyme 
superfamily is due to its active site that can bind a wide variety of structurally different 
compounds, often in multiple orientations. Moreover, the multiplicity of CYP enzymes, 
each with its own characteristics, have in many cases overlapping substrate selectivity 
(Anzenbacher et al., 2001).  
CYPs are the major catalysts in phase I metabolism in humans, being responsible for 
approximately 75% of the metabolism of prescribed drugs (Rendic et al., 2012; Rendic 
and Guengerich, 2015). The majority of human CYP reactions is mediated by a set of five 
CYPs (1A2, 2C9, 2C19, 2D6, and 3A4) with a major role for the CYP3A4 isoform. Minor 
contributions are ascribed to CYP2C8, 2A6 and 2E1 (Figure 1.1). Interestingly, the 
isoforms know to be responsible for bioactivation of chemicals to toxic products (see 
below), such as CYP1B1, 2A6, and 2E1, contribute only in a minor extent to the 
metabolism of xenobiotics in general (Rendic and Guengerich, 2015) (Figure 1.1).  
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Table 1.1. Classification of Human CYPs Based on Major Substrate Class. 
* X-ray crystal structure(s) reported (for human enzyme). **Animal orthologue (Rat or rabbit X-ray crystal structure). 
Mitochondrial CYPs are highlighted. Adapted from Guengerich FP, personal communication, 2017. 
 
 
 
 
 
 
 
 
 
Steroids Xenobiotics Fatty acids Eicosanoids Vitamins Unknown 
1B1 1A1* 2J2 4F2 2R1** 2A7 
7A1* 1A2* 2U1 4F3 24A1** 2S1 
7B1 2A6* 4A11 4F8 26A1 4A22 
8B1 2A13* 4B1** 5A1 26B1 20A1 
11A1* 2B6* 4F11 8A1* 26C1  
11B1 2C8* 4F12 (2W1) 27B1  
11B2 2C9* 4V2  27C1  
17A1* 2C18 4F22    
19A1* 2C19* 4X1    
21A2* 2D6* 4Z1    
27A1 2E1*     
39A1 2F1     
46A1* 3A4*     
51A1* 3A5*     
 3A7     
 3A43     
Figure 1.1. CYP isoforms involved in metabolism of all chemicals, according to Rendic and 
Guengerich (2015). The percentages represent the participation of individual CYP isoforms in 
metabolism of xenobiotics. CYP isoforms are represented as individual X-ray structures (from 
Šrejber et al., 2018). 
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Although the majority of CYP reactions involves the introduction of polar groups to 
parent compounds, enabling their detoxification and excretion, this may cause reversibly 
bioactivation, e.g. of chemical carcinogens. Many carcinogens are pro-carcinogens (i.e. 
are relatively non-reactive) but require metabolic activation to exert their genotoxic 
effects (Guengerich and Isin, 2008; Reed et al., 2018). Oxidative activation of 
carcinogens by CYP enzymes leads to the formation of highly reactive electrophilic 
intermediates which may react with nucleophilic centers of cellular constituents, such as 
proteins, RNA and DNA. This latter may give rise to DNA adducts and lesions which 
potentially may cause mutations (Nebert and Dalton, 2006). For example, aflatoxin B1 
(AfB1), a very potent hepato-carcinogen, is by itself relatively inert, but is metabolized 
in the liver, by CYP1A2 and 3A4, leading to the formation of highly reactive genotoxic 
and carcinogenic metabolites (Kamdem et al., 2006). 
 
1.2.1 Catalytic Cycle of CYPs 
CYP enzymes catalyze a variety of oxidation and some reduction reactions, collectively 
involving thousands of substrates (Guengerich et al., 2007, Table 1.1). Although CYPs 
are named cytochromes (electron-transferring proteins) they are in fact oxygenases, in the 
sense that they transfer electrons to oxygen and catalyze the oxidation of organic 
chemicals. CYP catalyze oxidations of many different types of substrates. Specifically, 
they are generally known as ‘monooxygenases’ or ‘mixed-function oxidases’ 
(Guengerich et al., 2016).  
For catalytic activity, CYPs require a source of electrons which are provided by reduced 
pyridine nucleotides. However, CYPs do not receive electrons directly from these 
cofactors, requiring auxiliary redox protein partners to shuttle the electron to the heme 
moiety in the active site. Depending on the cellular location and their redox partners, 
CYPs are generally divided into two major classes, class I and class II. Class I includes 
mitochondrial and some bacterial CYPs, which in their activity depend on two separate 
redox partners, consisting of an iron–sulfur protein (ferredoxin/adrenodoxin) and a flavin-
containing reductase (ferredoxin/adrenodoxin reductase). The class II CYPs are 
microsomal (i.e. located on the endoplasmic membrane) monooxygenases that receive 
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electrons from CPR, the founding member of the diflavin reductase family (Paine et al., 
2005; Lamb and Waterman, 2013). 
Microsomal CYP receives two electrons, donated by CPR one at a time at two distinct 
steps of the reaction cycle (Figure 1.2). By this sequential ET, CYP activates molecular 
oxygen (O2) and mediates the transfer of one atom of the activated O2 into the substrate 
and reduce the other atom into water (see scheme in Figure 1.2). Substrate RH is 
hydroxylated by the CYP to form the oxidized product ROH, and a water molecule is 
released as a byproduct of this reaction. In each monooxygenation reaction cycle, the two 
electrons are supplied by CPR functioning as an electron donor by accepting two electrons 
from NADPH, in the form of hydride (H-) and transferring them to CYP during catalysis. 
The CYP reaction can be summarized as: RH + O2+ NADPH + H
+ ROH + H20 + 
NADP+ (Denisov et al., 2005; Barnaba et al., 2017). 
Alternatively, the second electron can be donated by CYB5 (see Figure 1.2) (Paine et al., 
2005; Scott et al., 2016). CYB5 is a small heme protein (15 kDa), involved in lipid and 
sterol biosynthesis, and is found together with CPR anchor on the cytoplasmic side of the 
ER of eukaryotic cells through a hydrophobic transmembrane binding domain (Vergeres 
and Waskel, 1995, Wang et al., 1997). CYB5 is thought to promote catalysis not only via 
ET of the second electron, but also through allosteric regulation (Porter et al., 2002). 
Depending on the CYP isoform involved, substrate and experimental conditions, CYB5 
has been shown to stimulate, inhibit, or not to interfere with CYP reactions but its mode 
of action is still not fully understood (Bart and Scott, 2017). 
The efficiency of CYP catalysis is measured in terms of “coupling”, i.e. the amount of 
transferred electron that is committed to the monooxygenase activity versus the extent of 
the “uncoupled” (or unproductive) pathways. Three unproductive pathways exist (see 
Figure 1.2): (a) release of superoxide from the ferrous dioxygen (the autoxidation shunt), 
(b) release of hydrogen peroxide (the peroxide shunt), and (c) the 4e− reduction of heme 
to produce water (the oxidase shunt) (Denisov et al., 2005; Barnaba et al., 2017).  
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Figure 1.2. The catalytic cycle of CYP. The binding of substrate RH (1) causes a decrease of 
the redox potential, which allows the first ET from CPR (2). The reduction of Fe3+ to Fe2+ makes 
O2 binding suitable (3), which now can accept a second electron from either CPR or CYB5 (4), 
to form a hydroperoxyl intermediate known as compound 0. The O2−2 complex reacts with 
surrounding protons to form the highly reactive oxyferryl intermediate, also known as compound 
I (5). The Fe-ligated O atom (6) is transferred to the substrate forming a hydroxylated form of the 
substrate (7). The product is finally released (8), replaced by a molecule of water. Three 
uncoupling reactions are shown as dashed lines, with the respective products: (a) the autoxidation 
shunt (O2), (b) the peroxide shunt (H2O2), and (c) the oxidase shunt (H2O) (from Barnaba et al., 
2017). 
  
a 
b 
c 
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1.2.2 CYP Isoforms used in the studies of this thesis: CYP1A2, 
2A6 and 3A4 
Studies of this thesis involved three human CYPs, namely CYP1A2, 2A6 and 3A4, which 
are major isoforms in drug metabolism. In this section these three CYPs will be discussed 
more in detail. 
CYP1A2 belongs to the CYP1 family which comprises three functional genes in two 
subfamilies (see Table 1.1). The highly conserved CYP1A1 and CYP1A2 genes consist 
of seven exons and six introns and are located on chromosome 15q24.1 (Jiang et al., 
2005). Catalytic activities of the CYP1 enzymes are overlapping and include 
hydroxylations and other oxidative transformations of many polycyclic aromatic 
hydrocarbons and other aromatic substances. Whereas CYP1A1 prefers planar aromatic 
hydrocarbons, CYP1A2 shows a preference for aromatic amines (e.g. 2-aminoanthracene 
(2AA)) and heterocyclic compounds (e.g. 2-amino-3-methylimidazo(4,5-f)quinoline (IQ) 
and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)) (Duarte et al., 2005a/b, 
Guengerich and Isin, 2008). CYP1 enzymes play a prominent role in the bioactivation of 
procarcinogens, such as benzo[a]pyrene, arylarenes, nitroarenes, and arylamines present 
in charbroiled food and industrial combustion products to reactive and carcinogenic 
intermediates able to cause DNA damage (Zanger and Schwab, 2013). 
CYP1A2 is the main enzyme of CYP family 1, corresponding to approximately 10% of 
total CYP-content of the human liver (Parkinson and Ogilvie, 2008). The crystal structure 
of CYP1A2 revealed a rather compact active site with a cavity larger than that of CYP2A6 
but much smaller compared to CYPs 3A4 and 2C8 (Sansen et al., 2007a). Prototypical 
biotransformations catalyzed by CYP1A2 include 7-ethoxyresorufin O-deethylation, 
phenacetin O-deethylation, and caffeine N3-demethylation to paraxanthine, which are 
commonly used as probe-substrates for in vitro or in vivo phenotype determination (Zhou 
et al., 2004).  
In humans, CYP1A2 is constitutively expressed in the liver at high levels. In this organ, 
CYP1A2 plays a significant role in the metabolism of several clinically important drugs, 
including analgesics and antipyretics (acetaminophen, phenacetin, lidocaine), 
antipsychotics (olanzapine, clozapine), antidepressants (duloxetine), anti-inflammatory 
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drugs (nabumetone), cardiovascular drugs (propranolol, guanabenz, triamterene), among 
others (Zanger and Schwab, 2013). 
The CYP-allele website (https://www.pharmvar.org/) lists to date 41 defined alleles 
variants, some of which are associated with altered expression levels or code for proteins 
with altered enzyme activity. Because of the role of CYP1A enzymes in the metabolism 
of procarcinogens and cellular signaling molecules, their polymorphisms have been 
extensively studied as susceptibility factors in the context of various cancers (Zanger and 
Schwab, 2013).  
CYP2A6 is a member of the CYP2 family, which comprises 16 full-length genes, each 
containing 9 exons and 8 introns. The genes are located on different chromosomes and 
organized in multi-gene clusters containing one or several subfamilies. The human 
CYP2A genes are found in a 370 kb gene cluster on chromosome 19q13.2, containing 
genes and pseudogenes of the CYP2A, 2B, 2F, 2G, 2S and 2T subfamilies (Nelson et al., 
2004). The CYP-allele website lists currently 89 defined alleles and haplotype variants 
for CYP2A6. 
Human CYP2A6 is mainly expressed in the liver and corresponds to 7% of its CYP 
content (Parkinson and Ogilvie, 2008). CYP2A6 has been recognized as the major 
isoform involved in the oxidative metabolism of the psychoactive tobacco ingredient 
nicotine to the inactive cotinine (Raunio and Rahnasto-Rilla, 2012). The crystal structure 
of CYP2A6 revealed an active site cavity suitable for nonplanar low molecular weight 
molecules (Sansen et al., 2007b). The 7-hydroxylation of coumarin is a selective marker 
activity for CYP2A6 used in vitro experimentations (Fuhr et al., 2007). 
CYP2A6 was identified as the main isoenzyme responsible for bioactivation of the cancer 
prodrug tegafur (Komatsu et al., 2000), the 7-hydroxylation of the anti-HIV drug 
efavirenz and the biotransformation of the aromatase (CYP19A1) inhibitor letrozole 
(Murai et al., 2009). Furthermore, CYP2A6 contributes to the metabolism of a number of 
clinically used drugs (Di et al., 2009). CYP2A6 is involved in the bioactivation of 
carcinogens, including nitrosamines such as NNK, a major tobacco procarcinogen (Su et 
al., 2000); aromatic amines present in smoke, and AfB1 (Nakajima et al., 2006; Rossini 
et al., 2008). Most pharmacogenetic studies involving CYP2A6 were to delineate the 
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effect of genotype either on nicotine metabolism, smoking behavior, nicotine withdrawal 
symptoms or lung cancer risk (Benowitz et al., 2006; Nakajima et al., 2006; Mwenifumbo 
and Tyndale, 2007; Rossini et al., 2008).  
CYP3A4 belongs to the CYP3 family, which consists only of one subfamily, CYP3A, 
located on chromosome 7q22.1 and has a size of 231 kb. It comprises four CYP genes 
3A4, 3A5, 3A7, and 3A43 (Nelson et al., 2004). The CYP3A subfamily enzymes play a 
major role in drug metabolism (Zanger et al., 2008; Zanger and Schwab, 2013). The CYP-
allele website lists currently 53 defined alleles and haplotype variants for CYP3A4. 
The active site of CYP3A4 is large and flexible and can accommodate and metabolize 
many, preferentially lipophilic compounds with comparatively large structures (Scott and 
Halpert, 2005; Hendrychová et al., 2011). Typical large substrates are 
immunosuppressants, such as cyclosporine A and tacrolimus, macrolide antibiotics e.g. 
erythromycin, and anticancer drugs including taxol. Still smaller compounds are also 
accepted including ifosfamide, tamoxifen, benzodiazepines, several statins, 
antidepressants, opioids and many others (Zanger and Schwab, 2013). 
Although several probe drugs that measure general CYP3A activity are available, e.g. 
midazolam, erythromycin, alprazolam, and dextromethorphan (Fuhr et al., 2007; Liu et 
al., 2007), phenotyping data obtained with different CYP3A substrates are not generally 
well correlated to each other. This is a CYP3A4-typical feature that may be related to the 
occurrence of several overlapping substrate binding regions and the well-known allosteric 
regulation of CYP3A4 enzyme activity (Niwa et al., 2008; Foti et al., 2010; Roberts et 
al., 2011). Nevertheless, some limited substrate and regioselectivity differences were 
observed. Several probe-substrates are being used for CYP3A4, for in vitro activity 
evaluations (Ghosal et al., 2003), e.g. the fluorogenic substrate dibenzyl fluorescein 
(DBF). 
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1.3 NADPH dependent P450 oxidoreductase 
The human multi-domain CPR, is encoded by the POR gene located on chromosome 
7q11.2. This protein is a multidomain diflavin reductase, approximately 80 kDa, 
containing 680 amino acids (RefSeq protein: NP_000932, UniProt P16435). Evidence for 
the requirement of CPR in microsomal hydroxylation reactions was first obtained by La 
Du et al. (1955) and Gillette et al. (1957) in experiments in which cytochrome c was 
shown to inhibit the NADPH-mediated oxidative demethylation of monomethyl-4-
aminoantipyrine by liver microsomes. When Williams and Kamin (1962) and Phillips 
and Langdon (1962) published their characterization studies of CPR, they showed that 
this enzyme was localized in the ER of hepatocytes and, therefore, it was unlikely that 
cytochrome c was its natural electron acceptor. In fact, the inhibition of drug 
demethylation by cytochrome c predated the discovery of CYP by Omura and Sato (1962) 
and the demonstration by Estabrook et al. (1963) that the photochemical action spectrum 
of the reversal of carbon monoxide inhibition of steroid or drug hydroxylation 
corresponded to the reduced CO-bound CYP difference spectrum, indicating its role as 
the terminal oxygenase (Masters and Marohnic, 2006). 
Currently, it is known that CPR is the sole obligatory electron donor for all mammalian 
microsomal CYP proteins, but also of other redox-partner dependent enzymes such as 
heme oxygenase (HO), squalene monooxygenase (SQLE) and CYB5 (Guenguerich, et 
al., 2005; Pandey et al., 2010) (see Figure 1.5). CPR plays therefore a key role in multiple 
physiological pathways involving redox metabolic processes such as the metabolism of 
steroid hormones, vitamins, drugs and xenobiotics (Pandey et al., 2010; Miller et al., 
2011).  
 
1.3.1 Electron-transfer function 
Multidomain enzymes belonging to ET systems, such as CPR are generally comprised of 
transporter and reductase domains, assembled with connecting and hinge domains. CPR 
is a microsomal membrane-bound diflavin-protein attached to the cytoplasmic side of the 
ER via an N-terminal transmembrane hydrophobic anchor, approximately 55 amino acids 
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long (Figure 1.3 A). The domains that bear the two cofactors are a flavodoxin-like FMN-
binding domain (transporter) and a ferredoxin-NADPH reductase like FAD-binding 
domain (reductase) (Porter et al., 1990; Murataliev et al., 2004). A third highly flexible 
stretch, called the hinge segment, links the FMN and the connecting/FAD domain (Wang 
et al., 1997; Grunau et al., 2006; Grunau et al., 2007; Ellis et al., 2009) (Figure 1.3). In 
mammalians, CPR shares highly conserved amino acid sequences which form the binding 
domains for FMN, FAD and NADPH. Additionally, both the FAD- and NADPH-binding 
domains are similar to the FAD and NADPH binding domains of ferredoxin reductases 
and nitric oxide synthases (Waskell and Kim, 2015). 
CPR transfers electrons between cofactors in a precise and timely controlled manner, 
from NADPH through the FAD and FMN coenzymes to the final acceptor such as CYP 
(NADPH → FAD → FMN → CYP) (Murataliev et al., 2004; Aigrain et al., 2012; Iyanagi 
et al., 2012; Paine et al., 2005). Reduced FMN transfers the electrons one at a time to the 
redox partners of CPR (Masters et al., 2005). 
 
1.3.2 CPR protein conformation 
The first X-ray diffraction studies on soluble (N-terminal deleted) rat CPR showed a 
tightly packed and compact structure in which the two isoalloxazine rings of FMN and 
FAD are juxtaposed for ET between the two flavins (Wang et al., 1997). Subsequently, 
several other crystallography studies (Lamb et al., 2006; Xia et al., 2011b; McCammon 
et al., 2016) as well as Nuclear Magnetic Resonance (NMR) analysis of soluble human 
CPR (Vincent et al., 2012) showed similar closed structures. Another study, using a CPR 
mutant in which the FMN domain was linked to the FAD domain via a disulfide bridge, 
demonstrated a compact structure with the two flavins in a clear competent state for ET 
from FAD to FMN with a short inter-flavin distance (Xia et al., 2011a). In this closed 
structure, CPR was fit for internal flavin ET but unable to reduce external acceptors unless 
the disulfide bridge was reduced, allowing the re-opening of the protein structure. Since 
the closed conformation of CPR is incompatible for ET to redox partners, the occurrence 
of inter-domain motions was suggested to render the FMN domain accessible for ET to 
external cytochrome acceptors such as CYPs (Pudney et al., 2011).  
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In 2009, three separate studies reported on the existence of “open” or extended 
conformations of CPR (Hamdane et al., 2009; Aigrain et al., 2009; Ellis et al., 2009). The 
conformational study using X-ray crystallography of a CPR variant with a 4-amino acid 
deletion (ΔTGEE) in the hinge region, which connects the FMN domain to the remaining 
of the protein demonstrated three remarkably extended conformations (Hamdane et al., 
2009). The protein was defective in its intramolecular ET between the two flavins. 
However, it was able to successfully reduce CYP, by external chemical reduction of the 
FMN group. In this deletion mutant, the FMN domain was structurally rearranged, 
separated from FAD and exposed for interaction with its redox partners.  
In a second study of that year, an active CPR chimera, in which the FMN domain was 
replaced with its yeast counterpart was produced (Aigrain et al., 2009). Crystal structures 
of this fusion protein demonstrated different extended conformations from those of 
previously solved structures. The enzyme has a complete disrupted interface between the 
FAD and the FMN domain but remains functional for cytochrome c or CYP reduction, 
although with a strong decrease in efficiency. Both the distance between the flavins and 
the differences in flavin redox potentials indicated that CPR can undergo large 
conformational changes. Disturbing either the hinge region (ΔTGEE) (Hamdane et al., 
2009) or the interface FMN (yeast)-FAD (human) of CPR (Aigrain et al., 2009) leads to 
an open conformation, nonetheless still active with CYP.  
A third study by Ellis et al. of the same year, provided evidence for the existence of a 
second conformation in which the FMN domain is involved in a different inter-domain 
interface (Ellis et al., 2009). Small Angle X-ray Scattering (SAXS) analysis showed that 
oxidized and NADPH-reduced human CPR had different overall shapes. Additional 
NMR studies showed a mixture of approximately equal amounts of two forms of CPR. 
These newly found open CPR conformations were compatible with ET to redox-partners.  
The data of these three studies of 2009 taken together implied the presence of a control 
mechanism, devoted to opening and closing of the domains, in the course of the catalytic 
cycle (Pudney et al., 2011). 
Subsequent studies which were reported until the start of this PhD research, clearly 
established that human CPR co-exists in these two different types of conformations 
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(closed and open) which exist in a conformational equilibrium (Ellis et al., 2009; Huang 
et al., 2013; Jenner et al., 2011; Frances et al., 2015) (Figure 1.3 B). Molecular dynamic 
(in silico) studies suggested the transition between states to occur through a swinging and 
rotational movement (Sündermann and Oostenbrink, 2013), which was experimentally 
shown to be a rapid switch (600 s-1) (Frances et al., 2015). Dynamics of CPR requires 
substantial spatial reorganization in the protein (Sugishima et al., 2014) leading to the 
accessibility of the FMN to external electron acceptors (Grunau et al., 2007) such as 
cytochrome c, being reduced with a turnover rate of approximately 3000 min-1 
(Guengerich et al., 2009), i.e. more than 10 times slower than the open-closed frequency 
mentioned above. Conformational equilibrium has been shown to be dependent on the 
redox state of CPR and the binding of NADPH (Huang et al., 2005; Ellis et al., 2009) as 
well as pH and ionic strength (Frances et al., 2015). Notwithstanding, the structural 
determinants of the CPR protein that control the conformational changes, particularly in 
relevant physiological conditions, were poorly known. To elucidate this point is the main 
objective of this thesis (see section 1.5).  
 
1.3.3 The hinge segment of CPR 
Linker regions in proteins are important components of the dynamic identity of structures, 
providing flexibility and contributing to allostery and conformational changes of the 
protein, induced by the binding of substrate, or regulator molecules (Papaleo et al., 2016). 
The linker domain (LD) of human CPR connects the FAD and FMN domains through a 
highly flexible hinge (Wang et al., 1997; Grunau et al., 2006; Grunau et al., 2007; Ellis 
et al., 2009). The hinge is a specific section of the CPR protein that forms a loop, 
encompassing Gly235 to Tyr248, which has no particularly defined secondary structure 
(Wang et al., 1997; Xia et al., 2011a). The hinge segment has been postulated to play a 
major role in CPR’s protein dynamics, allowing the FMN-binding domain to “swing” 
into and out of position to allow ET from the reduced FAD, through the FMN, to the 
heme moiety of its redox partners (Hamdane et al., 2009; Laursen et al., 2011) (Figure 
1.3).  
1. INTRODUCTION 
17 
 
Figure 1.3. Structure of human CPR. (A) Domain organization in POR gene: Hydrophobic N-
terminal transmembrane (TM) domain; Co-factors binding domains FAD/FMN; Linker domain 
(LD) inserted in the FAD domain; connecting domain containing a flexible loop (hinge) (numbers 
indicate estimated amino acid positions) (by M. Kranendonk). (B) Model of the protein dynamics 
of CPR in its ET function and conformational equilibrium. CPR is represented on the membrane 
as it would be when attached by its N-terminal hydrophobic anchor. Left, the compact form, 
represented by the crystal structure, appropriate for interflavin ET. Right, the extended form, with 
the FMN exposed, appropriate for ET to CYP (adapted from Ellis et al. 2009, by M. Kranendonk). 
 
Certain residues in the hinge segment of CPR have been suggested to be important for 
the transition between closed and open conformations. In the study with the human-yeast 
chimera described above, Aigrain and colleagues suggested residues G240 and S243 to 
be of importance for large conformational changes in the protein (Aigrain et al., 2009). 
Subsequently, the in silico molecular dynamics study mentioned above, seem to reveal 
residues I245 and R246 as part of the conformational axis on which the opening and 
rotational movement of CPR occurs (Sündermann and Oostenbrink, 2013). These 
residues seem to be pivotal in the movement of the FMN domain relative to the remainder 
of the protein.  
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1.3.4 CPR genetic variations  
Genetic variations of the POR gene, encoding human CPR, have been found both in 
healthy individuals (genetic polymorphisms) and in patients with POR deficiency, know 
as the Antley-Bixler Syndrome or ABS1 (OMIM # 201750), caused by rare genetic 
mutations. The syndrome ranges from mild clinical manifestations to severe forms of 
congenital adrenal hyperplasia, severe skeletal malformation and genital ambiguity, 
thought to be caused by perturbed steroidogenesis, visceral anomalies (particularly of the 
genitourinary system), among other clinical manifestations (Huang et al., 2005; Dhir et 
al., 2007; Miller et al., 2011; Pandey et al., 2013).  
The structural POR mutations are scattered over the multi-domain CPR protein (Figure 
1.4) and several have been found to be difficult for structural interpretation (Pandey et 
al., 2013). Some of these mutations are located at structural areas supposedly important 
for ET control from CPR to CYP. Others were found to interfere directly with the binding 
of CPR’s cofactors (NADPH, FMN and FAD), which in some cases lead to severe losses 
of function (Kranendonk et al., 2008; Marohnic, et al., 2010). However, a number of 
these mutations did not seem to interfere directly with cofactor binding, demonstrating 
only partial loss of function (Nicolo et al., 2010; Agrawal et al., 2010; Fluck et al., 2010; 
Chen et al., 2012; Moutinho et al., 2012; Pandey and Sproll, 2014; McCammon et al., 
2016).  
Several of these mutations might be expected to interfere with CPR protein dynamics, 
altering structural requirements necessary for the optimal transition between 
conformations, perturbing the interaction of CPR with its redox acceptors. Some of these 
mutations seem to have a differential effect depending on the CYP isoform interacting 
with CPR (Dhir et al., 2007; Moutinho et al., 2012). Studies on the impact of genetic 
variations in POR affecting drug metabolism in healthy human population are at an early 
stage, and more information is needed to clarify the differences in metabolism due to 
variations in POR (Pandey et al., 2013). 
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Figure 1.4 Model of human CPR showing the locations of the sequence variants identified. 
The model described by Huang et al., (2005) based on the crystal structure of rat CPR lacking 65 
N-terminal residues (Wang et al., 1997). The α-carbon backbone is depicted as a narrow ribbon, 
the FAD and FMN moieties (magenta) and NADPH (cyan) are depicted as ball-and-stick models, 
and the variant amino acids are depicted by packed sphere images of different colors (from Huang 
et al., 2008). 
 
1.3.5 Multiple Redox partners 
CPR is attached to the cytoplasmic side of the ER via a transmembrane segment at its N-
terminus, together with its redox partners. CPR is the obligatory electron supplier of all 
microsomal CYP, thereby controlling the function of major metabolic systems involving 
microsomal CYP enzymes: steroid synthesis in adrenal glands and gonads, cholesterol 
synthesis (e.g. in developing bone), retinoic acid metabolism and metabolism of sterols, 
drugs and other xenobiotics, mainly in the liver.  
Drug-metabolizing microsomal CYP enzymes include major isoforms CYP1A2, 2C9, 
2C19, 2D6 and 3A4; steroidogenic microsomal CYP enzymes are CYP17A1 (17α-
hydroxylase/17,20 lyase), 21A2 (21-hydroxylase) and 19A1 (aromatase); while 
CYP51A1 (14α-lanosterol demethylase) is involved in sterol synthesis and metabolism 
(Tomalik-Scharte et al., 2010).  
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CPR also donates electrons to other non-CYP key enzymes such as HO, the unique 
enzyme responsible for the initial as well as rate limiting reaction for heme degradation 
(Schacter et al., 1972); SQLE, rate limiting enzyme for ergosterol and cholesterol 
biosynthetic pathways, catalyzing the epoxidation of squalene across a C–C double bond 
to yield 2,3-oxidosqualene in a reaction more typical of CYP-type oxidations (Ono and 
Bloch, 1975) and although not uniquely may reduce CYB5 (Oshino et al., 1971; Waskell 
and Kim, 2015) (Figure 1.5). 
 
 
 
Figure 1.5. Involvement of CPR in central metabolic pathways and its physiological 
implications (adapted from Tomalik-Scharte et al., 2010, by M. Kranendonk).  
 
 
Furthermore, CPR participates in the metabolism of several other xenobiotic molecules 
like mitomycin C, doxorubicin, ferricyanide, paraquate, dichlorophenolindophenol 
(DCPIP) and nitro blue tetrazolium, either directly reducing these compounds or as an 
electron donor to the actual catalyst (Pandey et al., 2010, 2013). The surrogate substrate 
cytochrome c is reduced by CPR and serves as a model for ET in CYP reactions as it 
requires two electrons donated by the FMN moiety of CPR (Pandey et al., 2013).  
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CPR has thus a very heterogeneous group of redox partners (Figure 1.5). The mechanisms 
of recognition and the determinants of CPR’s promiscuity in physiological acceptors 
remain largely unclear, although general electrostatic and hydrophobic interactions have 
been suggested (Hlavica et al., 2003; Kandel and Lampe, 2014).  
 
1.3.6 CYP:CPR Interaction  
Eukaryotic cells typically possess a multitude of different CYPs, which are tissue and 
cell-type specific, co-localized on the membrane of the ER and share the same protein 
partners CPR and CYB5 in a mixed-function oxidase system (Davydov et al., 2015; Reed 
et al., 2018). The membrane of the ER seems to form a scaffold, allowing proper 
alignment and functional interaction of these enzymes (Reed et al., 2013). 
Interaction between CPR and CYP is necessary for NADPH-dependent ET to the heme 
proteins. The ratio of CYP enzymes to CPR in the liver ER is in favor of CYP, generally 
in excess of 5-10:1 (Paine et al., 1997; Venkatakrishnan et al., 2000). The competition of 
CYP for CPR implicate a structural organization of the excess CYP around limiting CPR 
molecules to effectively receive electrons (Davydov et al., 2010; Reed et al., 2013).  
The binding of the different substrates to CYPs can enhance the affinity of CYPs for CPR 
or increase the CYP reduction potential, thereby providing a more efficient reduction by 
CPR (Das and Sligar, 2009). The structural constraints imposed by the anchoring of CPR 
and CYPs in the membranes provide an efficient way to form specific CPR–CYP 
complexes, which are needed for efficiency, since a single CPR supports multiple CYPs. 
Insertion of these proteins within the membrane restricts their ability to interact to two 
dimensions. However, owing to the flexibility of the proteins within the membrane due 
to the fluid mosaic model of biological membranes, their movement around their 
membrane-binding segments results in a greater range of motion and increases their 
ability to form productive complexes (Scott et al., 2016). The local lipid environment 
plays a role as constitutions of the membrane have been shown to affect interaction and 
ET of CPR to partner proteins (Das and Sligar, 2009). The heterogeneity in composition 
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of the membrane can also affect CYP function by either concentrating or segregating 
proteins within membrane regions (Scott et al., 2016). 
CPR–CYP interactions are influenced by many factors including the type of CYP, 
availability of substrates and ionic strength of the system (Backes and Kelley, 2003; 
Praporski et al., 2009; Farooq and Roberts, 2010). The interaction of CPR with CYP and 
other electron acceptor proteins seems mainly to be guided by electrostatic interactions, 
but there is also some evidence for a hydrophobic component (Nadler and Strobel, 1988; 
Strobel et al., 1989). These interactions in its association with a CYP may assist in the 
stabilization of CPR into an effective conformation (Pochapsky et al., 2003). 
Higher order of interactions between the components of the CYP monooxygenase system 
seem to allow more complex means of altering metabolism by the CYP enzymes – 
through the formation of CYP-CYP complexes (Davydov and Helpert 2008; Reed et al., 
2012; Reed et al., 2018). Evidence seems to indicate that the CYP enzymes and CPR may 
exist as a mixture of various complexes in the membrane, where both homomeric 
(Davydov et al., 2010; Reed et al., 2011; Davydov et al., 2013) and heteromeric (Reed et 
al., 2010) associations of CYP enzymes with CPR are likely to occur. In several of the 
mentioned reports, these types of complexes were shown to alter the enzyme activity for 
substrates (Reed et al., 2018).  
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1.4 Heterologous expression of human biotransformation 
enzymes 
The science of in vitro drug metabolism has shown remarkable progress in the recent two 
decades. With an increased understanding of drug-metabolizing enzymes and their roles 
in the metabolism of specific drugs, it is possible to apply a more mechanistic approach 
in assessing drug metabolism. Currently, there exists a wide array of in vitro 
methodologies to assess CYP catalysis and its modulation by xenobiotics (Ong et al., 
2013).  
Approaches utilize simple and robust bioanalytical assay techniques to probe CYP 
enzyme kinetics using different enzyme sources. For example, through cloning of the 
cDNA of the proteins using recombinant DNA techniques and their heterologous 
expression in bacterial, yeast and mammalian cell systems. These in vitro methods allow 
the expression of the human enzymes directly in the target cell, increasing sensitivity in 
the detection, e.g. mutagenicity (Kranendonk et al., 2000).  
The heterologous expression of human biotransformation enzymes in bacteria, namely in 
Escherichia coli (E. coli), has several advantages since it is cost effective, the organism 
is easy to manipulate genetically and may produce high levels of protein expression 
(Kranendonk et al., 2000; Ong et al., 2013). However, use of E. coli systems are limited 
to enzymes that are not dependent on post-translational modifications, such as 
phosphorylation and glycosylation (Cain et al., 2014). In the case of expressing 
mammalian CYPs, E. coli does not contain any endogenous CYP which could form a 
confounding factor when performing activity evaluations (Kranendonk et al., 2000). 
Moreover, E. coli allows the simultaneous expression of human CYPs with its 
corresponding CPR for proper catalytic activity studies (Kranendonk et al., 1999b). 
However, this bacterium possesses a bacterial (cytosolic) reductase system capable of 
sustaining mammalian CYP activity, albeit very inefficiently (Kranendonk et al., 1998).  
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1.4.1 Bacterial system used for the functional study of CPR  
A bi-plasmid system for the co-expression of CPR with a particular human CYP form in 
E. coli was previously engineered in our laboratory and developed by Kranendonk et al. 
(Kranendonk et al., 1999a/b). The initial strain was engineered for mutagenicity testing 
and was derived from tester strain BMX100 (Kranendonk et al., 1998), which detects 
efficiently chemical mutagenicity, monitored by the reversion to L-arginine auxotrophy, 
due to a mutation in the L-Arginine biosynthesis operon (genetic target argE3) 
(Kranendonk et al., 1996). From this initial human CYP competent tester strain several 
improved derivatives were developed, of which strain BTC-CYP is currently in use 
(Duarte et al., 2005). This humanized bacterial system demonstrated to be a robust in 
vitro model for mechanistic and functional studies of CPR (Moutinho et al., 2012; 
McCammon et al., 2016) and CYP-variants (Palma et al., 2010; Palma et al., 2013). 
BTC-CYP bacteria contain a bi-plasmid system for the co-expression of both CYP and 
CPR (Duarte et al., 2005, Kranendonk et al., 2008), through expression vectors pCWori-
CYP (Fisher et al., 1992) and pLCM_POR (Kranendonk et al., 1998; Kranendonk et al., 
1999a/b) (Figure 1.6). Vector pCWori is an E. coli expression vector conferring 
ampicillin resistance. CYP expression is driven by two consecutive pTAC promoters, 
under the control the LacIq repressor, inducible by isopropyl β-D-thiogalactoside (IPTG) 
(Figure 1.6 B). Vector pLCM_POR confers kanamycin resistance and contains cDNA 
encoding full length human CPR. CPR expression is driven by a single pTAC promoter, 
controlled by the presence of the LacIq repressor (encoded by the pCWori vector), and as 
such co-induced by IPTG. The presence of mucAB operon activates the mutagenic DNA 
repair system (error-prone), increasing detection of mutagenicity (Kranendonk et al., 
1998; Mortelmans and Zeiger, 2000) (Figure 1.6 A). 
This bi-plasmid expression system in E. coli leads to the simultaneous expression of the 
human CYP complex proteins which are correctly inserted in the bacterial inner cell 
membrane and fully active, reflecting in vivo activities and representing the in vivo 
stoichiometry of the membrane bound enzyme complex in the ER (CPR:CYP 1:5-10) 
(Paine et al., 1997; Venkatakrishnan et al., 2000; Kranendonk et al., 2000; Duarte et al., 
2005).  
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(A) 
  pLCM_POR    
(B) 
 
 
 
 
 
 
Figure 1.6. Bi-plasmid co-expression system of human CYP-competent cell model.  
(A) pLCM_POR expression vector for CPR variants. (B) Expression vector (pCWori) for 
different isoforms of representative human CYP (by M. Kranendonk). 
 
The maintenance of the correct stoichiometry of the CYP complex proteins in in vitro 
approaches is important to approximate the system as close as possible to physiological 
conditions. The CPR/CYP stoichiometry is considered as a major determining factor in 
the catalytic behavior of mammalian CYPs (Moutinho et al., 2012). In vivo, the CPR/CYP 
ratio is in favor of CYP, i.e. CPR is in the sub-molar range relatively to CYP as mentioned 
above. In vitro molecular and mechanistic studies of CYP catalysis should therefore avoid 
the use of artificial CPR/CYP stoichiometries, generating kinetic data with few relevance 
to human in vivo activities. In the experimental approaches used in this thesis, the in vivo-
like CPR:CYP stoichiometry was obtained by specific characteristics of the bi-plasmid 
system of BTC, using two different types (classes) of plasmids for the co-expression of 
the two enzymes: i) the pCWori-CYP and pLCM_POR vectors have different origin of 
replications, preventing plasmid incompatibility, and thus allow the coexistence of both 
plasmids in the same cell; ii) plasmids have different copy numbers (pCW: medium-high 
and pLCM_POR low copy number) and iii) each plasmid expresses its cDNA through a 
relatively strong (pCW: double pTAC promotor) and weak promotor (pLCM_POR: 
single pTAC promotor). 
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1.5  Aim and outline of this thesis 
 
1.5.1 Aim 
At the beginning of this PhD study in 2014, there was a scarcity in data on the structural 
features controlling the conformational changes in CPR’s open/closed protein dynamics 
in its ET function. Several residues in the hinge segment had been suggested to have a 
pivotal role in the transition between conformations but little was known on the role of 
the hinge segment in the mechanism of CPR’s gated ET in the interaction with its redox 
partners. 
The aim of this thesis was to unravel the molecular mechanism of CPR’s gated ET by 
disclosing structural determinants in its protein dynamics when sustaining structurally 
different redox partners in their activity. In particular, specific residues in the hinge 
segment were studied, to understand how these control the dynamic structural 
organization and conformational equilibrium of CPR in its ET function. This was pursued 
by changing specific hinge residues and studying their effect, both on the interaction with 
a frequently used, but non-physiological, surrogate redox partner of CPR, cytochrome c, 
and as well as with several natural redox partners, such as human CYP isoforms. Three 
specific representative human CYP isoforms involved in drug metabolism were used, and 
as such could contribute to the understanding of the role of CPR protein dynamics on 
CYP-mediated drug metabolism. This will further enhance the knowledge of 
pharmacokinetic/toxicokinetics of the human metabolism of drugs, xenobiotics and 
others.  
Additionally, as CPR may be considered as a prototype of diflavin reductases, these 
studies may furthermore contribute to the understanding of multidomain redox systems 
such as nitric-oxide synthase, methionine synthase reductase, dihydropyrimidine 
dehydrogenase and NADPH-dependent diflavin oxidoreductase 1 (Lienhart et al., 2013). 
This may assist in the unravelling of the precise control of the catalytic cycle of these 
reductases, the coupling with their redox partners and their involvement in relevant 
human physiological pathways, additionally helpful in understanding their role in specific 
disease states. 
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1.5.2 Outline of this thesis 
Section 1: Introduction 
In the first section, a general introduction to the work presented in this thesis is provided. 
CPR conformational model and its interaction with redox partners are discussed. In this 
context, the CYP superfamily and specific isoforms are outlined. Concepts like 
biotransformation and electron-transfer enzyme function are introduced. Heterologous 
human protein expression in bacteria is discussed. 
Section 2.1: The hinge segment of CPR in conformational switching: the critical role 
of ionic strength 
In section 2.1, the construction by site-directed mutagenesis and characterization of eight 
CPR hinge mutants, both in the soluble and membrane-bound form, are described. The 
reduction of the non-physiological substrate cytochrome c by these CPR mutants is 
evaluated at different salt (NaCl) concentrations, to assess the role of ionic strength in 
CPR’s dynamics. 
Section 2.2: The role of the hinge of CPR in the interaction with cytochrome P450 
In section 2.2, three CPR hinge mutants selected from the original eight mutant forms 
were combined with three human CYPs. Several functional assays were employed to 
assess the role of these hinge residues in CPR interaction with these natural redox 
partners, including the effect of ionic strength on these interactions.  
Section 3: Discussion and conclusions 
Main findings of this research are discussed in section 3, regarding the role of the hinge 
segment of CPR in its ET function, the factors that control the protein’s conformational 
equilibrium and CPR’s capacity in sustaining activity of structural diverse redox partners. 
A summary and conclusions of the present research are described. Future perspectives in 
the study of CPR functioning are presented. 
Section 4: Annexes 
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2.1 The Hinge Segment of Human CPR in Conformational 
Switching: The Critical Role of Ionic Strength 
 
This section was transcribed from a peer-reviewed paper, featured in an e-book published 
by Frontiers in Pharmacology: 
D. Campelo, et al. (2017). “The hinge segment of human NADPH cytochrome P450 
reductase in conformational switching: the critical role of ionic strength”. Front 
Pharmacol. 8:755. DOI: 10.3389/fphar.2017.00755. 
D. Campelo, et al. (2018). “The Hinge Segment of Human NADPH-Cytochrome P450 
Reductase in Conformational Switching: The Critical Role of Ionic Strength” In Pandey, 
A. V., Henderson, C. J., Ishii, Y., Kranendonk, M., Backes, W. L., Zanger, U. M., eds. 
Role of Protein-Protein Interactions in Metabolism: Genetics, Structure, Function. (pp-
125-137). Lausanne: Frontiers Media. DOI: 10.3389/978-2-88945-385-6. ISBN 978-2-
88945-385-6. 
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2.1.1 ABSTRACT 
NADPH-cytochrome P450 reductase (CPR) is a redox partner of microsomal cytochrome 
P450 and is a prototype of the diflavin reductase family. CPR contains 3 distinct 
functional domains: a FMN-binding domain (acceptor reduction), a linker (hinge), and a 
connecting/FAD domain (NADPH oxidation). It has been demonstrated that the 
mechanism of CPR exhibits an important step in which it switches from a compact, closed 
conformation (locked state) to an ensemble of open conformations (unlocked state), the 
latter enabling ET to redox partners. The conformational equilibrium between the locked 
and unlocked states has been shown to be highly dependent on ionic strength, reinforcing 
the hypothesis of the presence of critical salt interactions at the interface between the 
FMN and connecting FAD domains. Here we show that specific residues of the hinge 
segment are important in the control of the conformational equilibrium of CPR. We 
constructed six single mutants and two double mutants of the human CPR, targeting 
residues G240, S243, I245 and R246 of the hinge segment, with the aim of modifying the 
flexibility or the potential ionic interactions of the hinge segment. We measured the 
reduction of cytochrome c at various salt concentrations of these 8 mutants, either in the 
soluble or membrane bound form of human CPR. All mutants were found capable of 
reducing cytochrome c yet with different efficiency and their maximal rates of 
cytochrome c reduction were shifted to lower salt concentration. In particular, residue 
R246 seems to play a key role in a salt bridge network present at the interface of the hinge 
and the connecting domain. Interestingly, the effects of mutations, although similar, 
demonstrated specific differences when present in the soluble or membrane-bound 
context. Our results demonstrate that the electrostatic and flexibility properties of the 
hinge segment are critical for ET from CPR to its redox partners.  
Keywords: diflavin reductase, protein dynamics, multidomain proteins, conformational 
exchange, electron transfer, protein–protein interaction 
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2.1.2 INTRODUCTION 
Monooxygenase enzymes occur in all kingdoms of life and CYPs represent the largest 
superfamily of them (Lamb and Waterman, 2013; Munro et al., 2013). In mammals, 
microsomal CYPs catalyze the oxidation of a wide variety of essential endogenous and 
xenobiotic compounds (Coon, 2005; Rendic and Guengerich, 2015) by a two-electron 
activation of molecular oxygen, whereby one atom of oxygen is inserted into the organic 
substrate and the other is reduced to water (Guengerich, 2007). The catalytic cycle of 
CYP enzymes depends on redox partners for electron delivery. The CPR is strictly 
required for the activity of microsomal CYPs, while CYB5 can potentially be a donor 
molecule, albeit only for the second ET step (Scott et al., 2016).  
Human CPR, encoded by the POR gene, is a 78-kDa multidomain diflavin reductase that 
binds both FMN and FAD and is attached to the cytoplasmic side of the ER via a 
transmembrane segment at its N-terminus. The domains that bear the two cofactors are: 
a flavodoxin like FMN-binding domain and a ferredoxin-NADPC reductase like FAD-
binding domain. The third domain, called the hinge segment, links the FMN and the 
connecting/FAD domain. Electrons flow through CPR from NADPH to oxidized FAD as 
a hydride ion transfer to the FAD N5 atom, then, one by one, from the FAD to the FMN, 
then from the FMN hydroquinone to external acceptors, with the FMN cycling mainly 
between the hydroquinone and the blue semiquinone states (Murataliev et al.,1999). 
Although studies of CPR have predominantly focused on its role in CYP catalysis, CPR 
also support ET to other enzymes like HO (Schacter et al., 1972), SQLE (Ono and Bloch, 
1975), dehydrocholesterol reductase (DHCR) (Nishino and Ishibashi, 2000), and though 
not uniquely, CYB5, involved also in fatty acid desaturation and elongation reactions 
(Oshino et al., 1971). The determinants of this promiscuity in physiological acceptors are 
not yet known, however, they might indicate that the mechanisms of recognition of this 
heterogenic group of redox partners by CPR are probably not highly stringent. 
The first X-ray diffraction studies on soluble rat CPR showed a surprising compact 
structure in which the distance of FAD to FMN was about 4 Å, the two isoalloxazine 
rings almost coplanar and some parts of the FMN domain tightly packed against the rest 
of the CPR protein (Wang et al., 1997). This conformation, referred thereafter as part of 
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a locked state, was easily ascribed to the conformation allowing ET from FAD to FMN. 
Several other X-ray structures of CPR displaying the same spatial organization were 
subsequently obtained (Lamb et al., 2006; Xia et al., 2011b; McCammon et al., 2016). 
This conformational state as obtained in crystals, also occurs in solution (Vincent et al., 
2012). Furthermore, a CPR mutant in which the FMN domain was linked to the FAD 
domain via a disulfide bridge was competent for ET to the FMN moiety, ultimately 
proving that the locked state is fit for the internal flavin ET but is unable to reduce external 
cytochrome acceptors unless the disulfide bridge is reduced (Xia et al., 2011a). This led 
to the hypothesis that interdomain motions have to take place to render the FMN domain 
accessible to electron acceptors. 
The crystal structure of a mutant CPR in which the hinge segment was shortened by 
deletion of four residues (ΔTGEE) shows three different molecules per asymmetric unit. 
In each of them, the FMN domain is in a different position, more and more distant from 
the rest of the protein, whereas their connecting and FAD-binding domains are strictly 
superimposable, demonstrating a marked reorientation of the FMN domain relative to the 
FAD domain (Hamdane et al., 2009). Another evidence for domain mobility has come 
from the structural study of a chimeric enzyme consisting of the FMN-binding domain of 
yeast CPR and the remainder of the molecule, including the hinge segment, from human 
CPR (Aigrain et al., 2009). This chimeric enzyme, which is active in NADPH reduction 
of cytochromes c and CYP, displays a single, well-defined, molecule in the asymmetric 
unit. In this structure, the FMN domain is no longer making any interface with the 
connecting and FAD domains. Hence, large domain movements can happen in CPR (86 
Å distance between the two flavins). Furthermore, the redox potential of the flavins 
exhibit changes that maybe attributed to this large conformational change (Aigrain et al., 
2011). The various conformations in which the FMN domain is no longer making an 
interface with the FAD domain represent an ensemble of structures that can be designated 
as the unlocked state. SAXS studies on human CPR have also been crucial in 
demonstrating that, in solution, human CPR is in equilibrium between a closed, compact 
and a series of open, extended conformations (Ellis et al., 2009; Huang et al., 2013; 
Frances et al., 2015). The abovementioned mutant CPR containing a disulfide bond, 
though capable of NADPH mediated ferricyanide reduction, is essentially incapable of 
supporting CYP activity unless the disulfide bond is reduced (Xia et al., 2011a).  
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The ability of both flavin domains to move relatively back and forth from each other is 
thus a prerequisite for the FMN domain to interact with its physiological acceptors. 
However, the structural determinants that guide this conformational transition between 
open and closed forms, a process demonstrated to be essential for gating the interflavin 
ET in CPR and thus to its redox partners, are still not fully identified.  
It has long been known that ET from CPR to CYP displays a strong ionic strength 
dependency which demonstrated that the ET complex between the CPR and a CYP is, 
beside hydrophobic interactions, strongly based on charge pair interactions (Tamburini 
and Schenkman, 1986; Nadler and Strobel, 1988, 1991; Davydov et al., 1996, 2000; 
Bridges et al., 1998). Most of these studies evidenced that ionic interactions between CPR 
and its redox partners were the major determinants of the salt effects on CYPs activities 
and are reviewed in (Hlavica et al., 2003). However, we also demonstrated that the ionic 
strength effect on cytochrome c reduction by the soluble form of human CPR depends on 
the conformational equilibrium between the locked and unlocked states (Frances et al., 
2015). From the comparative studies of the open conformation seen in the chimeric yeast-
human CPR, two residues in the hinge, G240 and S243, were proposed to be important 
molecular determinants for the large conformational changes (Aigrain et al., 2009). 
Beside these two residues, I245 and R246 were also recently identified, in a molecular 
dynamics simulation study, as two essential residues of the hinge segment, forming a part 
of the conformational axis and involved in a rotational movement of the FMN domain 
relative to the rest of the protein (Sündermann and Oostenbrink, 2013). S243 and R246 
were also found to display large chemical shifts during the change in the conformational 
equilibrium between the locked and unlocked states (Frances et al., 2015). Additionally, 
the hinge segment was also found to be directly controlling ET to cytochrome c from the 
reductase domain of nNOS (Haque et al., 2007, 2012) as well as in CPR (Grunau et al., 
2007). 
In this work we have targeted four specific residues of the hinge segment indicated above, 
for site-directed mutagenesis to test their potential role in the conformational equilibrium 
of human CPR. By analyzing the salt-dependent changes of the cytochrome c reductase 
activity in the context of both soluble and membrane-bound forms of CPR, we propose 
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several hypotheses on the role played by these residues on the transition between the 
locked to the unlocked state, and thus in the ET mechanism of CPR. 
 
2.1.3 MATERIALS AND METHODS  
Reagents 
DCPIP and potassium ferricyanide were from Fluka (Buchs, Switzerland). L-Arginine, 
ampicillin, kanamycin sulfate, chloramphenicol, cytochrome c (horse heart), IPTG 
(dioxane-free), thiamine, glucose 6-phosphate, glucose 6-phosphate dehydrogenase, 
NADP+ and NADPH were obtained from Sigma–Aldrich (St. Louis, MO, United States). 
Phenylmethanesulfonyl fluoride (PMSF) was purchased from Gerbu Biotechnik GmbH 
(Heidelberg, Germany). Bacto agar, Bacto peptone and Bacto tryptone were obtained 
from BD Biosciences (San Jose, CA, United States). Bacto yeast extract was obtained 
from Formedium (Norwich, England). A polyclonal antibody from rabbit serum raised 
against recombinant human CPR obtained from Genetex (Irvine, CA, United States) was 
used for immunodetection of the membrane-bound CPR, while the respective antibody 
used the in the case of the soluble form of the enzyme was obtained from Thermofisher 
Scientific (Waltham, MA, United States). 
 
Construction and Cloning of the Different Mutants 
Soluble Forms of Human CPR 
Soluble CPR mutants, deleted of their first 44 N-terminal amino acids, were cloned by 
the Gibson method using a synthetic DNA fragment containing the desired mutation, with 
a compatible divergent PCR amplification of the plasmid pET15b expressing the soluble 
form of the human CPR, containing a N-terminal 6xHis tag. DNA sequencing confirmed 
the absence of any undesired mutations. The constructed plasmids were transformed into 
competent E. coli BL21 (DE3) cells for expression. 
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Membrane-Bound Forms of Human CPR 
Plasmid pLCM_POR (Kranendonk et al., 2008) was used for the expression of the 
membrane-bound, full-length forms of human CPR. Mutants containing alanine 
substitutions of residues I245 and R246 were initially obtained through standard site-
directed mutagenesis, using the sub-cloning vector pUC_POR, containing the initial 
segment (1–1269 bp) of human POR cDNA comprising the FMN and hinge domains 
(based on National Center for Biotechnology Information sequence NM_000941, 
encoding the CPR consensus protein sequence (NP_000932)). The mutated segments 
were obtained from the different mutated pUC_POR plasmids, using EcoRI + AatII 
restriction enzymes and cloned back into full-length CPR expression vector pLCM_POR. 
CPR mutants containing proline substitutions of residues G240, S243, I245 and R246 
were obtained by the Gibson method using a synthetic DNA fragment containing the 
desired mutation and a compatible divergent PCR amplification of the plasmid pET15b 
expressing the soluble form of human CPR. The mutated gene fragments were sub-cloned 
in vector pUC_POR using Megaprimer PCR of whole plasmid (MEGAWHOP) 
(Miyazaki and Takenouchi, 2002), followed by DpnI treatment. The mutated segments 
were obtained using Eco81I + SacI restriction enzymes and cloned back into the CPR 
expression vector pLCM_POR. The different constructed pLCM_POR plasmids were 
transformed into DH5a E. coli cells for plasmid propagation. POR cDNA of plasmids 
was fully sequenced to confirm the introductions of the designed mutations and the 
absence of any undesired mutations. CPR mutants were expressed in E. coli BTC, using 
the specialized bi-plasmid system for co-expression of CPR with human CYPs (Duarte et 
al., 2005). The pLCM_POR and the CYP-void plasmid pCWΔ (Kranendonk et al., 2008) 
were transfected through standard electroporation procedures (see annex 1). 
 
Protein Expression and Isolation 
Soluble Forms of CPR 
Protein expression in BL21 (DE3) cells was carried out at 29 ºC in Terrific Broth medium 
complemented with 1 mg.L-1 riboflavin and 100 mg.mL-1 ampicillin during 36 h (Frances 
et al., 2015). Cultures were spun down for 10 min at 7200 g and suspended in 20 mM 
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Na/K phosphate buffer pH 7.4 (buffer A). Cell lysis was achieved by 4 cycles of 
sonication (30 s of burst followed by intervals of 2 min for cooling) in buffer A containing 
a protease inhibitor cocktail (aprotinin 0.3 mM, leupeptin 1 mM, pepstatin A 1.5 mM, 
benzamidine 100 mM, metabisulfite 100 mM). Cell debris were removed by 
centrifugation at 8200 g for 1 h at 4 ºC. His-tagged proteins were bound on a TALON 
polyhistidine-TAG Purification Resin (Clontech, Mountain View, CA, United States), 
equilibrated with buffer A, containing 0.25 M NaCl and 0.25 M KCl, washed with this 
equilibrium buffer and eluted with a 0.25 M imidazole step gradient. Imidazole was 
eliminated from the eluted fraction by sequential washes in buffer A using a Vivaspin-15 
centrifugal concentrator (Sartorius, Goettingen, Germany). The protein solution was 
stored at 4 ºC in buffer A, containing 1 mM of both FMN and FAD. Purity of the sample 
was determined by SDS–PAGE and examination of the 280/450 nm ratio measured by 
optical spectroscopy. 
 
Membrane-Bound Forms of CPR 
Expression of the full-length membrane bound CPR mutants was obtained in BTC 
bacteria and membrane fractions of the different strains were prepared and characterized 
for protein content as described previously (Marohnic et al., 2010; Palma et al., 2013). 
CPR content of membrane fractions was quantified by immunodetection against a 
standard curve of purified human, full-length wild-type (WT) CPR, using polyclonal 
rabbit anti-CPR primary antibody and biotin-goat anti-rabbit antibody in combination 
with the fluorescent streptavidin conjugate (WesternDot 625 Western Blot Kit; 
Invitrogen). Densitometry of CPR signals was performed using LabWorks 4.6 software 
(UVP, Cambridge, United Kingdom) (see annex 1). 
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DCPIP and Ferricyanide Reduction Assay and Cytochrome c Reduction 
Microplate Assay 
DCPIP and Ferricyanide Reduction 
With DCPIP, assays were performed in 20 mM Tris-HCl buffer containing 1 mM EDTA, 
and various NaCl concentrations (from 50 mM up to 1.4 M), pH 7,4 at 25 ºC in the 
presence of 70 mM DCPIP. Initial rates were monitored at 600 nm using  
ΔεM = 21000 M-1.cm-1. With ferricyanide, assays were performed in the same conditions 
as described above, but in the presence of 1 mM ferricyanide. Initial rates were monitored 
at 420 nm using ΔεM = 1020 M-1.cm-1.  
 
Cytochrome c Reduction Activities  
Initial experiments were performed with soluble CPR. Cytochrome c reductase activity 
was followed at 550 nm (ΔεM = 21000 M-1.cm-1) with CPR concentrations ranging from 
2 to 20 nM. In cuvette assays, cytochrome c (100 mM final) and NADPH (200 mM final) 
were mixed in 20 mM Tris-HCl buffer containing 1 mM EDTA, and various NaCl 
concentrations (from 50 mM up to 1.4 M), pH 7.4 at 25 ºC. The reaction was initiated by 
adding CPR. A set of preliminary rate assays were performed in a microtiter plate format 
to optimize linearity of the reaction traces for the mutants, with conditions close to the 
traditional cuvette approach. In particular, the concentrations of CPR, cytochrome c and 
NADPH were varied in several control experiments to ensure linearity. In these assays, 
CPR and NADPH (200 mM final) were mixed and the reaction was started by diluting 
directly this mix in microplate wells containing 20 mM Tris-HCl buffer pH 7.4, 
supplemented with cytochrome c (100 or 200 mM) and the ad hoc NaCl final 
concentration (from 50 mM to 1.25 M) at 37 ºC. The reaction was monitored at 550 nm 
for 5 min in a PowerWave X select microplate reader (Biotek Instruments, Winooski, VT, 
United States).  
A first set of kinetic measurements was performed in triplicate using the two cytochrome 
c concentrations indicated above. A second set of triplicate experiments was repeated 
with another batch of purified CPR. Reduction velocities were found virtually equal when 
using cytochrome c at 100 or 200 mM (data not shown). Cytochrome c was subsequently 
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used in the microplate format at 200 mM (final concentration) for all kinetic 
measurements. CPR samples (soluble forms) were diluted up to concentrations giving 
linear velocity traces to compensate for lower or increased velocities, see Supplementary 
Table S2.1. Each kobs value is the average of six measurements: one triplicate using a first 
batch of enzyme and a second triplicate, using a second batch of purified CPR.  
The conditions of the microplate rate assay were then verified for the membrane-bound 
CPRs, to ensure linearity of the reaction traces. Reactions were followed for 4 min in a 
multi-mode microtiter plate reader (SpectraMax i3x, Molecular Devices) and each sample 
was assayed at least in triplicate. The optimal dilution of the membrane bound WT CPR 
was determined (0.5 pmol/mL), using 200 mM of cytochrome c, NADPH regenerating 
system (NADPH 200 mM, glucose 6-phosphate 500 mM and glucose 6-phosphate 
dehydrogenase 0,04 U/mL, final concentrations) and 372 mM NaCl in a 100 mM Tris 
buffer (pH 7.4). The same CPR dilution was applied in the cuvette assay under the same 
conditions except for cytochrome c (50 mM) and NADPH (200 mM, without 
regeneration) and was measured during 60 s, which resulted in virtually the same kobs as 
with the microtiter plate format assay. Finally, the membrane bound mutants were 
assayed with CPR well-concentrations, proportionally diluted as those determined for the 
soluble forms (see Sup. Table S2.1). Control experiments with E. coli (BTC) membranes 
without CPR expression demonstrated no cytochrome c reduction upon dilution (see 
annex 1). 
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2.1.4 RESULTS 
 
Ionic Strength Dependency of the ET of the Soluble Form of Human CPR to 
Three Artificial Acceptors 
In order to further understand the role of the ionic strength in ET from CPR to acceptors 
such as cytochrome c and discriminate between the two major hypotheses (salt-dependent 
conformational equilibrium or electrostatic interactions with the substrates), we analyzed 
and compared the ionic strength dependency of CPR toward DCPIP and ferricyanide with 
that of cytochrome c. DCPIP and ferricyanide have unique characteristics in term of 
charge and electron receiving capabilities (redox potential). Figure 2.1 shows the activity 
profiles of the soluble, WT form of human CPR in function of the ionic strength for 
cytochrome c-, DCPIP- and ferricyanide-reduction. 
Cytochrome c and DCPIP related graphs share the same bell-shaped curve. For 
cytochrome c, the concentration of NaCl giving the maximal kobs is around 400 mM, a 
value quite comparable to the one measured in our previous study (Frances et al., 2015). 
However, the maximum of kobs is different for DCPIP (575 mM). This difference might 
be attributed to the fact that DCPIP is an obligate two electrons (hydride) acceptor, which 
may have a different overall ET scheme compared to cytochrome c. The ionic strength 
dependent variation of kobs measured for the reduction of DCPIP and cytochrome c by 
soluble human CPR display both a bell-shaped profile. However, these substrates are 
different in term of net charge (cytochrome c contains + 9,5 charges at pH 7,0 while 
DCPIP is neutral). This result thus strengthens the hypothesis that the ionic strength 
dependency of electron flow from CPR to acceptors is mainly determined by the 
conformational equilibrium between the locked and unlocked states of CPR and only in 
a minor manner by electrostatic interactions between the FMN domain and the acceptor. 
We also analyzed the reduction of ferricyanide, another nonnatural substrate. 
Interestingly, the salt-dependent kobs profile is totally different from the ones seen with 
cytochrome c or DCPIP, being composed of two straight lines crossing at a NaCl 
concentration of around 450 mM. The constant rise of the kobs might be attributed to a 
gradual increase of the redox potential of ferricyanide due to the increase of ionic strength 
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in Tris-based buffers (O’Reilly, 1973). Therefore, the ferricyanide reduction, which 
mainly occurs at the FAD cofactor (Vermilion et al., 1981), may be relatively independent 
from the salt concentration and hence from the conformational equilibrium, a result that 
was previously observed with the ΔTGEE mutant (Hamdane et al., 2009). Interestingly, 
the inflection occurs around a salt concentration quite similar to the one yielding the 
maximum kobs with cytochrome c. However, we do not have any coherent explanation for 
the peculiar salt profile observed with this substrate.  
Based on these latter results, we decided to use cytochrome c reduction as an appropriate 
reporter to probe salt-mediated conformational equilibrium changes in ET of specific 
CPR mutants. 
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Figure 2.1 Variation of kobs in function of the ionic strength. The activity of the soluble, WT 
form of human CPR was assayed with various acceptors, namely cytochrome c (A), DCPIP (B) or 
ferricyanide (C). 
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Design of the Different Mutants 
The hinge segment is defined by a stretch of 14–15 amino acids that does not display any 
particularly defined secondary structure. It is also the only part of the CPR structure where 
evident structural changes can be seen when comparing the two open conformations of 
CPR (crystallographic structures of the ΔTGEE mutant and the yeast/human chimera) 
and the other closed conformations of CPR (yeast, human, rat). Residues G240 and S243 
(numbering according to the human CPR consensus amino acid sequence NP_000932) 
correspond to positions with strongly modified phi and psi angles between the closed and 
open forms (Aigrain et al., 2009). These two residues were therefore mutated into prolines 
in order to test if and how geometrical constraints modify the conformational equilibrium 
of CPR. Residues I245 and R246 were selected based on the observation that the 
backbone atoms of both residues were rotated in the ΔTGEE mutant or in the closed to 
open transition visualized by molecular modeling (Hamdane et al., 2009; Sündermann 
and Oostenbrink, 2013). For this last residue, we evidently switched the cationic Arg 
residue into a non-charged one (either Ala or Pro) while for the previous Ile residue, we 
preferred mutations affecting either the mobility/rigidity (Ile to Ala or Pro). Two double 
mutants, cumulating charge and flexibility changes were also designed for residues 
245/246. Finally, as the physiological form of CPR is membrane-bound and the 
membrane anchoring segment may have a profound influence on the equilibrium between 
locked and unlocked states or the open-closed exchange rates, we analyzed the effects of 
these mutations in both the soluble and membrane bound context. 
Based on these rationales, six single mutants (G240P, S243P, I245A, I245P, R246A and 
R246P) and two double mutants (I245A/R246A and I245R/R246I) were produced both 
in the soluble and membrane-bound (full-length) forms of CPR. Figure 2.2 provides a 
representation of the positions of the four targeted amino acids in the structure of the 
closed conformation of human CPR (5FA6, chain A) and on the structure of the open 
conformation of the yeast/human chimeric CPR (3FJO). The two structures (5FA6, chain 
A and 3FJO) were aligned onto the FAD domain (Figure 2.2A) or the FMN domain 
(Figure 2.2B). Both views provide the rationale for the design of our mutants: G240 
corresponds to the position where the hinge is tilted in the open conformation compared 
to the closed conformation (Figure 2.2A); S243 side chain orientation is different 
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between the two forms (Figure 2.2A); I245 and R246 show an interesting proximity and 
potential interaction with the connecting domain (Figures 2.2 A, B).  
 
Figure 2.2 Positions of the studied mutations in CPR. The structure of the yeast-human open 
form CPR chimera (3FJO, in dark green) and the WT soluble human closed form CPR (5FA6, 
chain A, in pink) were used to analyze the variations in the hinge segment between the closed and 
open form of CPR. Mutated residues are displayed as sticks of either green or magenta colors 
according to the structures. (A) Both structures were aligned onto their FMN domains. (B) Both 
structures were aligned onto their connecting/FAD domains. The figure was prepared using the 
PyMol software (Schrödinger, 2015). 
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Production of the Various Mutants of Human CPR 
Soluble Forms 
Eight different plasmids encoding the soluble CPR mutants G240P, S243P, I245A, I245P, 
R246A, R246P, I245A/R246A and I245R/R246I were introduced into E. coli and the 
various proteins expressed and purified as described in Section “Material and Methods.” 
SDS-PAGE gel analysis shows that the different mutant proteins present the same profile 
than the wild type (WT), with a major band just below 70 kDa which corresponds to the 
soluble form of the CPR (69 kDa). Biological duplication of the entire expression and 
purification stages was performed to ensure repeatability. Some discrete bands, at lower 
molecular weights compared to WT CPR were detected either with Coomassie staining 
or by western blot analysis (see Supplementary Figure S2.1), indicating some minor 
degradation of the purified enzymes. However, these represent less than 5% of the full-
length soluble CPR and hence would have a minor impact on the kinetic assays. All CPR 
mutants presented the same absorbance spectra as the WT soluble enzyme, with a 
maximum of absorption at 450 nm, indicating no or minor changes in the chemical 
surrounding of both flavins. Last, all mutants were obtained in the semiquinone form, like 
the WT CPR, indicating no major changes in the absolute redox potential values of the 
flavins in the mutant forms. These results emphasize that the introduced mutations did 
not apparently modify the surroundings of the flavins.  
 
Membrane-Bound Forms 
The eight different mutants were introduced in the E. coli BTC strain, expressed and 
bacterial microsomes were isolated, as described previously (Kranendonk et al., 2008). 
No expression problems were encountered, except for mutant G240P for which the level 
of expression was substantially lower than for the other mutants. Immunodetection of 
CPR in isolated microsomes showed only trace amounts of the G240P mutant protein, 
not sufficient for subsequent analysis. Other CPR mutants demonstrated expression levels 
comparable with the WT form (see Supplementary Figure S2.1).  
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Mutations Affect Differently the Soluble and Membrane-Bound Forms of 
CPR 
Assay Conditions 
Our study was designed to test the variation of cytochrome c reduction in various salt 
concentration conditions for nine CPR enzymes variants (WT + eight mutants) in the 
context of the soluble or membrane bound forms. We therefore developed and optimized 
a 96-well plate format assay to follow cytochrome c reduction. These experiments were 
performed at 37 ºC, contrarily to the primary test realized at room temperature in cuvette 
with the WT, soluble form of human CPR (Figure 2.1). Optimal conditions of the 
microplate rate assay were determined to ensure the linearity of the reaction traces. 
Initially, assays were performed at two cytochrome c concentrations (100 and 200 mM) 
in order to ensure that saturation was reached at all salt concentrations, which virtually 
gave the same velocities (data not shown). Subsequently cytochrome c was used at 200 
mM. CPR concentrations in the tests were also optimized to obtain linear traces for each 
mutant (both for the soluble and membrane bound forms) in order to compensate for 
lower or higher activities (see Supplementary Table S2.1). We verified that salt profiles 
were equivalent between the tests performed in the cuvette and in the 96-well plate format 
(data not shown). Figure 2.3A displays the salt profile of the WT as well as mutants in 
the context of their soluble form at 37 ºC. Clearly the WT profile is superimposable to the 
one in Figure 2.1, although minor differences can be seen, notably for the concentration 
of salt that gives the maximal value of kobs (425 mM at 25 ºC instead of 395 mM at 37 
ºC). This minor variation could be explained by the temperature shift from 25 ºC to 37 
ºC, probably favoring the opening mechanism and therefore the unlocked state. Apart 
from this difference, no other changes were noted and the comparison of the salt profiles 
of the mutants either in their soluble or membrane bound forms was pursued at 37 ºC, 
with the 96 well plate assay format. 
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The Hinge Partly Controls the Conformational Equilibrium of the Soluble 
CPR Form 
As mentioned earlier, the ionic strength dependency of cytochrome c reduction by CPR 
can be partly considered as a direct measure of the proportion of the locked vs. unlocked 
states (Frances et al., 2015) and the bell-shaped curve of this ionic strength dependence 
has been also reported in the ET from the flavodoxin of Desulfovibrio vulgaris to 
cytochrome b553 (Sadeghi et al., 2000). We therefore performed a full analysis of the 
ionic strength dependency of cytochrome c reduction for all single and double mutants 
(Figure 2.3). Figure 2.3A depicts the 8 different ionic strength profiles obtained with the 
various mutants compared with the WT one. All curves of the kobs vs. ionic strength 
display the same typical bell-shaped curve seen with the WT CPR. With the exception of 
the S243P mutant, all ionic strength profiles are shifted to the left (lower NaCl 
concentrations). Moreover, nearly all of them (except S243P and I245A) have lower 
maximal kobs values. This result indicates that the various introduced mutations have 
pronounced effects either on the conformational equilibrium or the ET efficiency, yet all 
of them are still active (lowest kobs is 30% of the one observed with WT CPR). The redox 
potentials of both flavins and cytochrome c are known to depend to some extent on the 
ionic strength. While for cytochrome c these changes are known and relatively small 
(Gopal et al., 1988), it is difficult to predict the changes that would occur for the flavins. 
Based on our observation that the microenvironment of flavins is probably not 
significantly altered between mutants and WT CPR (equal absorption spectra) we have 
based our working hypotheses on the assumption that the redox potential of the flavins 
are not functionally different between the mutants and the WT soluble or membrane-
bound forms of CPR. 
From Figure 2.3A, maximal kobs values were extracted and used to generate a graph 
comparing the salt concentration at which the maximum kobs occur and the maximal kobs 
value itself (Figure 2.3B). The case of S243P and I245A is interesting. Both have 
approximately the same kobs (slightly higher than the WT for S243P). However, I245A 
denotes a clear difference in term of optimal ionic strength contrarily to S243P and WT. 
Another example is the situation for I245A, G240P and I245P, for which the optimal ionic 
strengths are identical, yet the three mutants have different maximal kobs values. Hence 
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these data seem to indicate a separation between the efficiency of cytochrome c reduction 
and the conformational equilibrium of CPR (represented by the salt concentration at 
which the maximal kobs occurs). However, globally, when the profiles are shifted to lower 
ionic strength the maximal kobs values are lower. 
The effects on the conformational equilibrium are interesting and merit further analysis. 
With the exception of S243P, all mutants either favored the unlocked state or stabilized 
the locked state. The introduction of a proline residue (G240P, I245P and R246P) 
probably imposes strong constraints on the hinge and may therefore stabilize discrete 
conformations of the unlocked state. The removal of the positive charge of the arginine 
residue at position 246 (R246A) may loosen the potential interactions between the hinge 
and the connecting domain and also destabilize the locked state. It should also be noted 
that the double mutants present the maximal displacements in term of salt profile and that 
the charge suppression at position 246 cannot be compensated by the introduction of an 
arginine at position 245 (see the double mutant I245R/R246I). 
Lower maximal kobs values are probably associated to some decrease in the rate constants 
of one or several ET steps. We already demonstrated that conformational exchange occurs 
at a much faster rate than ET (Frances et al., 2015). Hence, during the course of steady 
state activity, CPR opens and closes several times before electrons are transferred from 
FAD to FMN. This also means that the locked state might actually have several closed 
conformations, not all of them productive for inter-flavin ET, a feature that has already 
been described (Hay et al., 2010). Therefore, the mutants might disfavor the occurrence 
of productive conformations in the locked state, hereby reducing the maximal kobs value. 
Hence, although there would not be a direct relationship between conformational 
equilibrium and maximal kobs, the effects of some of the mutations on the destabilization 
of the locked state could also change the rate limiting step. 
 
  
2. RESULTS 
64 
 
 
 
 
  
Figure 2.3 Variation of the kobs for cytochrome c reduction in function of the ionic strength for 
the WT and mutants of the soluble forms of human CPR. Cytochrome c reduction assays were 
performed in triplicate in 96 well microtiter plates as described in the Material and Methods section. 
(A) Salt dependent profile of the kobs with the WT and the mutants. Symbols depicting the different 
mutants are included in the panel. (B) Maximal kobs values were extracted from panel A and plotted 
as a function of the salt concentration. Symbols depicting the different mutants are identical as the 
ones in (A). kobs values represent the average of three replicates and the error bars depict the standard 
deviation. 
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The Hinge Controls the Conformational Equilibrium of the Membrane 
Bound CPR 
The same mutants, when present in the full-length, membrane anchored form, were 
subsequently studied. Figure 2.4 presents the same analysis of both the variation of kobs 
and the optimal ionic strength value for each of the mutants in the context of the 
membrane bound form. Our first striking result is that the ionic strength giving the 
maximum kobs for the WT membrane bound form is shifted to higher salt concentrations 
compared to the WT soluble form, indicating a stronger interaction between the two 
domains (Figure 2.4A). Various hypotheses can be formulated to account for this fact. 
First, the presence of the negatively charged phospholipid heads of the membrane 
probably modifies the electrostatic potential around the FMN domain, potentially 
strengthening the interactions between the two flavin domains and thus favoring the 
equilibrium toward the locked state. Second, the presence of the membrane close to the 
FMN domain might impeach movements of the FAD domain compared to those 
attainable with the soluble form. This restriction of movement could favor the closing 
mechanism, hereby stabilizing the locked state. 
Despite the above peculiarity of membranous CPR, Figure 2.4A shows that, as seen with 
the majority of the soluble forms, all mutants have their salt profiles shifted to lower ionic 
strengths when compared to the WT. This result confirms that the generated mutants have 
a greater tendency to favor the unlocked state, independently of the presence or absence 
of the membrane. Although differences exist between individual mutants depending on 
the context (soluble or membrane bound forms), again the maximal effects are seen with 
the R246 mutations and the double mutants containing mutations at the positions 246 and 
245.  
Maximal kobs values were also extracted and plotted against the corresponding salt 
concentration (Figure 2.4B). Overall, the salt concentration at which kobs is maximal 
covers a larger range with the membrane bound forms compared to the soluble forms. 
This indicates that the influence of salt on the conformational equilibrium is greater when 
CPR is attached to the membrane than when the various domains have more degree of 
liberty, i.e., when in the soluble form. 
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Interestingly, Figure 2.4B shows marked differences in the clustering of mutants 
compared to Figure 2.3B. This suggests again that the salt concentration giving the 
highest possible kobs (1:1 proportion of locked/unlocked states) does not correlate with 
the value of the kobs itself. This is particularly evident with the membrane-bound forms of 
the S243 and I245 mutants.  
Some parallels can be drawn between mutants in the soluble and the membrane bound 
forms from comparison of Figures 2.3B, 2.4B: (i) the group which had lower cytochrome 
c reduction rates in the soluble form (R246A, R246P, I245R/R246I and I245A/R246A) 
have almost the same kobs than the WT in the membrane bound form and, (ii) the group 
that had similar cytochrome c reduction rates than the WT in the soluble form (S243P, 
I245A and I245P), display a greater efficiency of ET to cytochrome c in the membrane 
bound form.  
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Figure 2.4 Variation of the kobs for cytochrome c reduction in function of the ionic strength 
for the WT and mutants of the membrane bound forms of human CPR. Cytochrome c 
reduction assays were performed in triplicate in 96 well microtiter plates as described in the 
Material and Methods section. (A) Salt dependent profile of the kobs with the WT and the mutants. 
Symbols depicting the different mutants are included in the panel. (B) Maximal kobs values were 
extracted from panel A and plotted as a function of the salt concentration. Symbols depicting the 
different mutants are identical as the ones in (A). kobs values represent the average of three 
replicates and the error bars depict the standard deviation. 
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2.1.5 DISCUSSION 
The role of the hinge segment in diflavin reductase enzymes was studied both in NOS 
enzymes (Haque et al., 2007, 2012) and in CPR (Hamdane et al., 2009), using either 
lengthening or shortening of the primary sequence. Our study was designed to address 
the role of specific residues of the hinge segment of CPR (G240, S243, I245 and R246) 
without modifying its length. We have analyzed the salt-induced changes in the 
conformational equilibrium between the locked and unlocked states, via cytochrome c 
reduction, in the context of both the soluble and membrane-bound forms of CPR. In our 
first set of experiments using the soluble form of WT CPR, we compared the ionic 
strength profiles of the kobs with three artificial substrates. Our results confirmed that the 
well-known salt dependency of either cytochrome c or CYP reductions (Voznesensky and 
Schenkman, 1992) can be mostly attributed to a change in the conformational equilibrium 
of CPR, between the locked state, non-competent in ET to cytochrome c and the unlocked 
state capable of transferring electrons from the reduced FMN to acceptors. However, as 
explained in Section “The Hinge Partly Controls the Conformational Equilibrium of the 
Soluble CPR Form” we cannot rule out that the redox potentials of the flavins in the 
mutants forms of CPR are equivalent. Still, as mentioned before, the fact that the 
absorption spectra of the different WT and mutant CPRs are indistinguishable indicates 
that the chemical environment of the flavins is similar in all studied proteins. In the rest 
of the discussion, we therefore assumed that these redox potentials are equal between all 
CPR forms studied, bearing in mind that the various properties of the mutants (especially 
the rate constants) might, to some extent, be attributed to these putative redox potentials 
changes. 
In the membrane bound form of WT CPR, the kobs is lower than the one measured with 
the soluble form, a feature already seen upon solubilization of CPR (Phillips and 
Langdon, 1962). A possible explanation is a potential restrictive access of cytochrome c 
to the FMN domain caused by the membrane, giving rise to the observed differences 
between the effects of mutations when present in the soluble or membrane bound forms. 
Interestingly, none of the introduced mutations were capable of completely abolishing the 
CPR ET to cytochrome c but rather displayed several intermediate features, either 
changing the salt profile or the efficiency of ET, or both. We thus hypothesize that the 
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targeted positions, although important, are only a part of the structural determinants 
promoting the conformational exchange between the locked and unlocked states. It is also 
worth noting that the ionic strength profiles obtained with all mutant forms (soluble and 
membrane bound, except for the soluble form of the S243P mutant) were shifted to lower 
salt concentrations compared to that of the WT CPR. This clearly indicates that the 
majority of changes that were introduced displaced the equilibrium toward the unlocked 
state. This is not completely surprising for the mutations that potentially enhance the 
flexibility (I245A) or removed salt bridges between the hinge and the connecting domain 
(R246A). However, for the mutations introducing proline residues in the hinge (G240P, 
S243P, I245P, R246P) the shift in the ionic strength profile might indicate that rigidifying 
these positions could result either in the destabilization of the locked state or the 
stabilization of the unlocked state. Still, the maintenance of a rather effective cytochrome 
c reduction in all cases might indicate that the loss of flexibility in the mutants bearing a 
proline residue may also be partly compensated by the hinge flexibility involving residues 
at other positions. 
The second interesting feature of our mutants is that we can separate the ionic strength 
profile from the efficiency of the ET to cytochrome c, i.e., there is no evident direct 
relationship between the salt concentration at which kobs is maximal and the value of kobs 
itself (Figures 2.3B, 2.4B). Thus, in our conditions, the rate limiting steps remain 
independent of the conformational equilibrium. The conformational exchange frequency 
between the locked and unlocked states is at minimum 600 s-1 (Frances et al., 2015), a 
value 10 times greater than the kobs observed with cytochrome c and coherent with the 
one determined by Haque et al., (2014). This also means that the locked state might 
actually have several closed conformations, not all of them productive for inter-flavin ET, 
a feature that has already been described (Hay et al., 2010). Hence, there would not be a 
direct relationship between conformational equilibrium and maximal kobs and the effects 
of our introduced mutations, destabilization of the locked state, could also affect the rate 
limiting step giving rise to either equal, lower or higher kobs values compared to the WT 
forms. 
In the soluble form of human CPR, only the S243P and possibly the I245A mutations 
have no effect on the rate of cytochrome c reduction. However, in the membrane bound 
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form, these two mutants, along with I245P, present cytochrome c reduction rates higher 
than the WT form, and higher than the soluble counterparts. To our knowledge, this is the 
first report of kobs values up to 8.000 min
-1 for ET to cytochrome c with CPR. However, 
these features were already observed in some mutants affecting the charge pairing 
between the FMN and FAD domains of nNOS (Haque et al., 2013) and in a C-terminal-
truncated version of murine iNOS in which cytochrome c reduction attained  
31.467 min-1 (Roman et al., 2000). In the nNOS mutants, the increase of kobs for 
cytochrome c reduction was attributed to a change of the conformational behavior. 
However, in our case, the maximal kobs was determined at a salt concentration where the 
conformational equilibrium corresponds to a 1:1 ratio of locked/unlocked states, as we 
demonstrated before (Frances et al., 2015). Therefore, the high maximal kobs values 
observed in the mutants may be attributed to a change in the FAD to FMN ET rate limiting 
step, because, in the case of cytochrome c reduction by CPR, this step is considered the 
slowest. Still, it should be reminded here that natural redox partners of CPR such as 
microsomal CYP, may have specific structural requisites to bind CPR and form 
productive electron-transfer complexes with its membrane anchored redox partners, a 
situation evidently different with soluble partners such as cytochrome c. The differences 
in our results for the soluble and membrane-bound forms seem to indicate that residues 
S243 and I245 of human CPR are playing a role in this specific aspect.  
Figure 2.5 depicts the position of the R246 amino acid in the structure of the WT, soluble 
form of human CPR (McCammon et al., 2016). The R246 is in close contact with two 
acidic residues (D445 and E449) present in the connecting domain (Figure 2.5A). 
Mutations at position 246 abolish a charge pairing with these two acidic residues. The 
distances of the three nitrogen atoms of R246 (NE, NH1 and NH2) with both terminal 
oxygens of D445 and E449 and the carbonyl oxygen of D445 are compatible with 
hydrogen bonds (Figure 2.5B). Furthermore, one terminal oxygen atom of E449 is also 
in a distance compatible to form a hydrogen bond with the amide nitrogen atom of Q247. 
This relatively strong hydrogen bonding network is evidently disrupted in the mutants 
changing R246 into any non-charged residue. The addition of a charge at the previous 
residue (in the double mutant I245R/R246I) does not restore the WT phenotype because 
I245 side-chain is clearly not oriented favorably in order to substitute for R246 in the 
complex hydrogen bonding network. This result is reminiscent of the mutations analyzed 
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by Shen and coworkers demonstrating a similar shift in the salt profile when removing 
potential ionic interactions between the FMN and the connecting domains by mutating 
E216 into a glutamine residue (Shen and Kasper, 1995). Our results thus demonstrate that 
the hinge segment also actively participates in the construction of the FMN/FAD 
interface. When the loss of critical ionic interactions modifies the equilibrium between 
the locked and unlocked states, the ionic strength at which the maximal value of kobs 
occurs is evidently lower, yet the maximum kobs value may remain roughly constant, as 
demonstrated by several of the mutant CPRs. 
 
 
 
 
 
 
 
 
  
Figure 2.5 Hydrogen bond network around residue R246 of human CPR. (A) Position of R246, 
Q247, D445 and E449 in the structure of the soluble form of WT human CPR. The color coding is 
as follows: FMN domain, cyan; hinge segment, green; connecting domain, orange; FAD domain, 
red. Flavins are depicted in yellow sticks, the various positions as stick in the same color code of the 
domain to which they belong. (B) Detailed view of the hydrogen bonding network. The color coding 
is the same as in (A). 
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A final remark should be made concerning the salt concentration at which the maximal 
kobs was observed for the WT, membrane bound form of CPR, which is around 500 mM 
NaCl. It is clear that the ionic strength at this salt concentration is much higher than the 
physiological one, 154 mM KCl (physiological serum). As such it seems that the 
conformational equilibrium of CPR, in vivo, is probably in favor of the locked state, 
thereby reinforcing the idea of an external trigger for opening CPR (Grunau et al., 2006, 
2007), such as the presence of membrane-bound CYPs which are physiologically 
outnumbering CPR molecules by a factor of 5–10 in the liver. How this competition for 
CPR is affected by the conformational equilibrium is still an open and intriguing question. 
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2.1.9 SUPPLEMENTARY MATERIAL 
Table S2.1: CPR concentrations used in cytochrome c reduction microplate assays. 
  Soluble CPR (nM) 
Membrane-bound 
CPR (nM) 
WT 6,1 0,50 
G240P 11,6 0,95 
S243P 2,8 0,23 
I245A 9,2 0,75 
I245P 4,4 0,36 
R246A 8,8 0,72 
R246P 9,4 0,77 
I245R+R246I 19,2 1,57 
I245A+R246A 4,4 0,36 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S2.1: Immuno-detection of membrane-bound (A, B) and soluble forms of human CPR 
(C). 
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2.2 Probing the Role of the Hinge Segment of Cytochrome P450 
Oxidoreductase in the Interaction with Cytochrome P450 
 
This section was transcribed from the following peer-reviewed paper: 
D. Campelo, et al. (2018). “Probing the role of the hinge segment of cytochrome P450 
oxidoreductase in the interaction with cytochrome P450”. Int J Mol Sci. 19 (12).  
DOI: 10.3390/ijms19123914.  
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2.2.1 ABSTRACT 
NADPH-cytochrome P450 reductase (CPR) is the unique redox partner of microsomal 
cytochrome P450s (CYPs). CPR exists in a conformational equilibrium between open 
and closed conformations throughout its electron transfer (ET) function. Previously, we 
have shown that electrostatic and flexibility properties of the hinge segment of CPR are 
critical for ET. Three mutants of human CPR were studied (S243P, I245P and R246A) 
and combined with representative human drug-metabolizing CYPs (isoforms 1A2, 2A6 
and 3A4). To probe the effect of these hinge mutations different experimental approaches 
were employed: CYP bioactivation capacity of pre-carcinogens, enzyme kinetic analysis, 
and effect of the ionic strength and cytochrome b5 (CYB5) on CYP activity. The hinge 
mutations influenced the bioactivation of pre-carcinogens, which seemed CYP isoform 
and substrate dependent. The deviations of Michaelis-Menten kinetic parameters 
uncovered tend to confirm this discrepancy, which was confirmed by CYP and hinge 
mutant specific salt/activity profiles. CPR/CYB5 competition experiments indicated a 
less important role of affinity in CPR/CYP interaction. Overall, our data suggest that the 
highly flexible hinge of CPR is responsible for the existence of a conformational 
aggregate of different open CPR conformers enabling ET-interaction with structural 
varied redox partners. 
Keywords: NADPH-cytochrome P450 reductase (CPR); microsomal cytochrome P450 
(CYP); Cytochrome b5 (CYB5); protein dynamics; electron-transfer (ET); protein–
protein interaction. 
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2.2.2 INTRODUCTION 
Microsomal cytochrome P450 (CYP) metabolism requires a coupled supply of electrons, 
which are donated by the auxiliary protein NADPH cytochrome P450 oxidoreductase 
(CPR). CPR, encoded by the POR gene, is a ~78-kDa electron-transferring diflavin 
enzyme anchored to the membrane of the ER [1]. CPR mediates a two-electron transfer 
(ET) per reaction cycle, originated from NADPH enabling CYP-mediated metabolism of 
many compounds. These include endobiotics, e.g., steroids, bile acids, vitamins and 
arachidonic acid metabolites, as well as many xenobiotics, including therapeutic drugs 
and environmental toxins [2,3]. Moreover, CPR is the unique electron supplier of heme 
oxygenase, squalene monooxygenase and fatty acid elongase [4], sustaining exclusively 
the activity of these enzymes. Cytochrome b5 (CYB5) can donate the second electron to 
CYP, competing with CPR for the binding site on the proximal side of CYP [5]. CYB5’s 
interaction may have either a stimulating, inhibiting or having no effect over CYP 
catalytic activity, which seems to be CYP isoform and even substrate dependent [6]. 
CPR comprises a number of structurally distinct domains namely an N-terminal 
hydrophobic membrane anchoring domain; two flavin binding domains for flavin adenine 
dinucleotide (FAD) and flavin mononucleotide (FMN); a LD joining the FMN and FAD 
domains, as the provider of structural flexibility; and an NADPH binding domain [7]. The 
hinge segment, a highly flexible stretch with no defined secondary structure links the 
FMN and the connecting/FAD domain [8–10]. Electrons are transferred from NADPH 
through FAD (reductase) and FMN (transporter) coenzymes of CPR to redox partners, 
such as to the heme group in the reactive center of CYP [11]. 
Initial structural studies of CPR identified compact conformations that allowed internal 
(inter-flavin) ET, but were unable to reduce external acceptors [8,12,13]. Subsequently, 
three separate studies identified different open structures of CPR that allowed ET to redox 
partners, indicative of domain motion of CPR [10,14,15]. It is now fairly established that 
CPR exists in a conformational equilibrium between open and closed states in its ET 
function, which is highly dependent on ionic strength conditions [10,16,17]. The 
transition between these states appears to occur through a rapid swinging and rotational 
movement [17,18]. Certain residues in the hinge region have been suggested to be of 
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importance for these large conformational changes [19], and seem to form a 
conformational axis, involved in a partial rotational movement of the FMN domain 
relative to the remainder of the protein [10,18]. 
Analysis of CPR domain dynamics is pertinent to understand its role in the interactions 
with its natural redox partners and its gated ET function. The affinities between CPR and 
CYP have been indicated among the factors modulating the protein dynamics of CPR. 
Different CYP isoforms may be differently served by CPR gating its ET differentially 
[20,21]. Although advances obtained during the last decade, CPR’s structural features 
controlling ET are not yet properly identified. CPR mutations may perturb specific 
structural requisites, necessary for the optimal transition between open and closed 
conformations, as well as disturb the interaction of CPR with its redox partners [10,20–
22]. 
Previously, we have studied the effect of mutations in CPR on its redox partners 
[20,22,23] and the effect of alterations in the hinge segment in CPR-dependent 
cytochrome c reduction [24]. These hinge mutations showed differential effects on the 
conformational equilibrium of CPR and ET efficiency to cytochrome c, a non-
physiological redox partner of CPR. Through modulation of the ionic strength conditions 
we demonstrated that electrostatic and flexibility properties of the hinge are critical for 
ET function, in which CPR’s membrane anchoring was shown to play an important role 
[24]. Although frequently used as a surrogate, the soluble cytochrome c has been 
indicated to interact differently with CPR, when compared with interactions of natural 
membrane-bound partners, such as CYP [25]. The use of cytochrome c as redox partner 
may have obscured additional important clues on structural features of the hinge segment 
involved in CPR’s open/closed dynamics and its gated ET function. To address this issue, 
three hinge mutants were selected from the initial eight mutants of our former study, based 
on their specific phenotypes in cytochrome c reduction. Human membrane bound CPR 
mutants S243P, I245P and R246A (numbering according to the human CPR consensus 
amino acid sequence NP_000932) were each combined with three different human CYPs, 
namely CYP1A2, 2A6 or 3A4, representatives of three major CYP families involved in 
drug metabolism [2,3]. The effect of the structural deviations of the three mutants was 
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probed to obtain further insights on the role of the hinge segment of CPR in the interaction 
and ET with these physiological redox partners, using different experimental approaches. 
 
2.2.3 RESULTS 
 
Bacterial co-expression of CPR mutants and CYP 
Wild-type CPR and CPR hinge mutants S243P, I245P and R246A were separately 
introduced in the E. coli BTC strain and co-expressed with CYP1A2, 2A6 or 3A4, using 
methods described previously [26,27]. CYP expression levels were determined in 
bacterial whole-cells (Table 2.1). When co-expressed with CPR variants, CYP expression 
levels varied between 109–241 nM, 96–130 nM and 105–143 nM for CYP1A2, 2A6 and 
3A4, respectively. Expression levels for these CYPs were comparable with those found 
previously with BTC strains [22,28,29]. More importantly, no large deviations were 
found in the CPR:CYP ratio between the four CPR variants, when expressed with each 
of the three CYPs (see Table 2.1). This enabled us to ascribe differences in activities of 
the CPR variants to the mutations, and not to variations in the stoichiometry between the 
two enzymes. These ratios were actually similar to those observed in our previous studies 
[22,28,29] and are in the range of those observed in human liver microsomes [30,31]. 
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Table 2.1 Microsomal cytochrome P450 (CYP) and NADPH cytochrome P450 oxidoreductase 
(CPR) contents of BTC cultures and membrane fractions. 
CYP Isoform CPR Form 
 
Whole-Cells Membrane Fractions 
 
CYP 1 CYP 1 CPR 1 CPR:CYP Ratios 
 (nM) (pmol/mg Protein) 
CYP1A2 
WT  109 ± 4 54 ± 1 4.1 ± 1.5 1:13 
S243P  241 ± 4 73 ± 4 7.7 ± 0.2 1:9 
I245P  206 ± 11 102 ± 1 6.1 ± 0.5 1:17 
R246A  176 ± 3 91 ± 2 5.4 ± 0.2 1:17 
CYP2A6 
WT  130 ± 2 139 ± 1 10.5 ± 1.3 1:13 
S243P  98 ± 1 106 ± 3 11.2 ± 0.5 1:9 
I245P  96 ± 7 102 ± 1 9.5 ± 0.9 1:11 
R246A  98 ± 2 146 ± 1 10.6 ± 1.5 1:14 
CYP3A4 
WT  105 ± 2 83 ± 3 19.8 ± 0.2 1:4 
S243P  122 ± 3 77 ± 2 22.5 ± 2.6 1:3 
I245P  128 ± 3 78 ± 2 18.3 ± 0.7 1:4 
R246A  143 ± 5 78 ± 1 21.4 ± 0.3 1:4 
1 CYP and CPR contents are mean ± sd. 
 
CYP-Activities When Combined with the Three CPR Hinge Domain Mutant 
Whole-cell Bioactivation assays 
A whole cell/bioactivation assay was used for the first evaluation of the effect of the three 
hinge mutations on the activity of the three CYPs. This approach made use of the 
applicability of the BTC-CYP bacteria in mutagenicity testing [26,28]. The levels in 
CYP-dependent bioactivation of different pre-carcinogens, namely 2AA (2-
aminoanthracene), IQ (2-amino-3-methylimidazo(4,5-f)quinolone), NNdEA (N-
nitrosodiethylamine), NNK (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone) and 
AfB1) were determined (Table 2.2; Figure 2.6). Interestingly, two of the three CPR hinge 
mutants lead to bioactivation capacities, which were either stimulated or equal, in 
comparison when CYPs were sustained by WT CPR, except for mutant I245P. This hinge 
mutant demonstrated a decrease for CYP1A2 and CYP3A4 mediated bioactivation of 
2AA and AfB1, respectively. In contrast, CYP1A2 and CYP2A6 bioactivation capacities 
(for IQ and NNdEA, respectively) were increased when assayed with this mutant, with 
no significant differences in CYP2A6 bioactivation of NNK. Seemingly, the effect of 
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CPR mutant I245P was CYP isoform and substrate dependent. The bioactivation capacity 
of all three CYPs was consistently augmented when assayed with CPR mutant R246A, 
i.e. all tested compounds demonstrated increased mutagenicity levels, in comparison with 
CYPs sustained by WT CPR. Mutant S243P demonstrated no significant differences in 
the bioactivation capacity of the three CYPs for the tested compounds, when compared 
with WT CPR. 
Table 2.2 CYP-mediated bioactivation of pre-carcinogens. 
CYP Isoform Mutagen 
 CPR form 
 WT  S243P  I245P  R246A 
CYP1A2 
2AA 1  5643 ± 271  5666 ± 177  3339 ± 145  6274 ± 106 
IQ 1  335 ± 8  323 ± 7  521 ± 104  1103 ± 253 
CYP2A6 
NNdEA 2  537 ± 14  543 ± 21  885 ± 122  929 ± 118 
NNK 2  770 ± 121  799 ± 110  788 ± 57  1014 ± 29 
CYP3A4 AfB1 1  1129 ± 97  1109 ± 115  661 ± 185  1616 ± 163 
Values are mean ± sd of three independent experiments, expressed as the number of revertant colonies per 
nmol 1 or per µmol 2 of pre-carcinogen.   
Figure 2.6 Bioactivation of pre-carcinogens mediated by CYP 1A2, 2A6 or 3A4 when 
combined with the three CPR hinge mutants. Bioactivation capacities were normalized with 
the one observed when CYPs were combined with WT CPR. (2AA: 2-aminoanthracene; IQ: 2-
amino-3-methylimidazo(4,5-f)quinoline; NNdEA: N-nitrosodiethylamine; NNK: 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone; AfB1: aflatoxin B1). 
2. RESULTS 
89 
 
Membrane Preparations 
CYP-Enzyme Kinetic Analysis 
Enzyme activities of CYP1A2, 2A6 and 3A4 were measured using specific fluorogenic 
probe substrates ethoxyresorufin (EthR), coumarin and dibenzylfluorescein (DBF), 
respectively). Reaction velocities could be plotted according to the Michaelis-Menten 
equation and kinetic parameters (kcat and KM) could be derived (Table 2.3). In general, 
CYP activities promoted by CPR mutants showed lower turn-over rates (kcat) and 
affinities (KM) when compared with WT that were also CYP form dependent. However, 
differences were minor in both constants and kcat/KM values were not significantly 
different from WT values for all tested CYPs (Table 2.3). 
Table 2.3 Michaelis-Menten kinetic parameters of CYP activities. 
CYP Isoform CPR Form 
kcat 1 KM 1 Efficiency 
(Product Formed     
pmol.min-1.pmol-1 CYP) 
(µM) (kcat/Km) (% WT) 
CYP1A2 
WT 0.62 ± 0.02 1.94 ± 0.16 0.32 (1.00) 
S243P 0.63 ± 0.01 1.23 ± 0.05 0.51 (1.59) 
I245P 0.40 ± 0.01 0.89 ± 0.04 0.46 (1.44) 
R246A 0.43 ± 0.01 0.74 ± 0.06 0.59 (1.84) 
CYP2A6 
WT 1.37 ± 0.07 1.99 ± 0.34 0.69 (1.00) 
S243P 1.17 ± 0.08 2.03 ± 0.40 0.58 (0.84) 
I245P 1.20 ± 0.09 1.78 ± 0.39 0.67 (0.97) 
R246A 1.53 ± 0.08 1.98 ± 0.33 0.77 (1.12) 
CYP3A4 
WT 2.53 ± 0.16  3.75 ± 0.55  0.67 (1.00) 
S243P 1.83 ± 0.08  3.07 ± 0.34  0.60 (0.88) 
I245P 1.89 ± 0.13  2.85 ± 0.50  0.66 (0.98) 
R246A 2.18 ± 0.22  3.82 ± 0.87  0.57 (0.85) 
1 kcat and Km values are expressed as mean values of three independent experiments ± sd, determined at 0 
M NaCl. 
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Ionic strength effect on CPR:CYP interaction 
We previously demonstrated that mutations in the hinge region of human CPR strongly 
influences ionic strength profiles of ET to cytochrome c [24]. Ionic strength dependency 
of CPR’s ET was thus analyzed via CYP activities measurement in presence of increasing 
NaCl concentrations (0–1.25 M) (Figures 2.7 and 2.8). Control experiments showed no 
effect of the salt concentration on the fluorescence of the formed products (Figure S2.3) 
or on the pH of the reaction mixture (data not shown). Interestingly, the maximum 
velocities of the three CYPs seem to occur at lower ionic strength conditions for all CPR 
(WT or variants) when compared to their maximum velocities in cytochrome c reduction 
reported in our previous study [24]. 
The salt dependence of CYP1A2 activity demonstrated a bell-shaped EthR O-deethylase 
activity curve with all CPR tested (Figure 2.7A), analogous to the ones described in our 
former study when measuring cytochrome c reduction [24]. The maximum activity 
(maximum kobs) was obtained, on average, at 100 mM NaCl. CYP1A2 activities dropped 
close to zero at the highest salt concentrations (1.25 M) for all CPR variants. CPR mutant 
S243P was more active than the WT, while other mutants showed lower activities when 
compared with WT. 
For CYP2A6 (Figure 2.7B), the coumarin hydroxylase activity profiles showed less 
dependence on ionic strength as with CYP1A2 and showed no drop in activity at the 
highest salt concentrations. Maximum velocities were obtained approximately at 150 mM 
NaCl. All CPR mutants presented lower activities when compared with WT CPR. 
CYP3A4 DBF O-debenzylase activity profiles (Figure 2.7C) were also bell-shaped, like 
CYP1A2, except for the CPR mutant R246A. The maximum activity was obtained, on 
average, at 100 mM NaCl. The activity dropped close to zero at the highest salt 
concentrations as was observed with CYP1A2. Interestingly, the CPR mutant R246A 
revealed a different salt profile with CYP3A4, leading to a continuous decrease of activity 
with increasing salt concentration, the maximal activity being even greater that the one 
obtained with WT CPR. 
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Figure 2.7 CYP reaction velocity (kobs) in of the NaCl concentration, for the WT and mutant 
forms of CPR with CYP1A2 (A), CYP2A6 (B) or CYP3A4 (C). 
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Figure 2.8 Relative CYP-reaction velocities (kobs) of CYP1A2, 2A6 and 3A4 in function of the 
NaCl concentration, when combined with CPR WT (A) or mutants S234P (B), I245P (C) and 
R246A (D). Velocities were normalized with the one observed when combined with WT CPR at 
0 M NaCl. 
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CYB5 effect on activity of CYP1A2, 2A6 and 3A4 
CYB5 may act as an alternative donor of the second electron in the CYP catalytic cycle. 
We thus studied the effect of CPR hinge mutations when associated with CYB5, to 
determine if the presence of an alternative electron donor partner, capable of competing 
with CPR for CYPs is an important issue in the function of the hinge segment. The effects 
of CYB5 on CPR/CYP combinations were analyzed through enzyme activity assays in 
the presence of increasing concentrations of CYB5 and thus different CYB5:CPR ratios 
(Figure 2.9 and Table 2.4). Enzyme activities were normalized to the activity measured 
in the absence of CYB5. While the effect of CYB5 on CYP activities was not major, some 
interesting differences could be seen, notably in the CYB5 concentration giving the best 
stimulus. While for CYP1A2, the maximal effect was observed at 150 nM of CYB5, for 
CYP2A6 the concentration of CYB5 giving this maximal effect was dependent on the 
mutation, ranging from 50 nM with the WT CPR to 400 nM for the R246A mutant of 
CPR. For CYP3A4, the effect was relatively constant between all CPR mutants, but the 
concentration of CYB5 needed to obtain the maximal stimulation was much higher (400 
nM). Overall, while CYP1A2 does not seem very sensitive to the presence of CYB5, a 
slight inhibition could be observed at high concentrations of CYB5. For the two other 
CYPs, the stimulation was quite pronounced, ranging from 2.6 to 3.4 or 1.8 to 2.6 for 
CYP2A6 and CYP3A4, respectively (Figure 2.9). No major differences were observed 
between CPR WT and mutants for each CPR/CYP combinations in term of the 
concentration of CYB5 to achieve the maximal effect, however, the intensity of the 
stimuli was different between CPR mutants. 
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Figure 2.9 Effect of CYB5 concentration on maximum reaction velocities of CYP1A2 (A), 2A6 (B) and 
3A4 (C) when sustained by WT CPR and the three hinge mutants. Activities were normalized to the one 
without CYB5 for each CPR mutant in comparison to WT. 
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Table 2.4 Effect of CYB5 on CPR/CYP combinations. 
CYP Isoform CPR Form Maximal kobs 1 
CYB5 Stimulus 2 
CYB5:CPR Ratio 3 
(%) 
CYP1A2 
WT 1.04 ± 0.01 100 163 
S243P 1.11 ± 0.02 107 118 
I245P 1.12 ± 0.04 108 208 
R246A 1.12 ± 0.02 108 211 
CYP2A6 
WT 3.40 ± 0.04 100 26 
S243P 2.72 ± 0.05 80 106 
I245P 2.69 ± 0.04 79 43 
R246A 3.15 ± 0.04 93 211 
CYP3A4 
WT 2.60 ± 0.01 100 66 
S243P 1.87 ± 0.02 72 55 
I245P 1.92 ± 0.00 74 68 
R246A 2.06 ± 0.02 79 67 
1 Normalized maximum enzyme activity: (kobs)/(kobs at 0 nM CYB5). Values are expressed as the mean of 
three independent experiments ± sd. 2 Maximum CYB5 stimulus of enzyme activity when CYPs were 
combined with mutant CPRs, relative to the ones obtained with CPR WT. 3 The ratio at which maximum 
kobs was reached. Grey shaded values: Maximum fold stimulation of enzyme activity by CYB5 when CYPs 
were combined with WT CPR. 
 
2.2.4 DISCUSSION 
Microsomal CYP-mediated metabolism is dependent on ET through protein:protein 
interaction with its primary redox partner CPR. Traditionally, membrane anchoring and 
a negatively-charged surface patch of CPR have been considered to be major 
determinants of the proper alignment in this interaction, in which hydrophobic 
interactions have also been implicated [32,33]. Still, the view on CPR:CYP interaction 
for ET has become increasingly more complex with the recognition of CPR protein 
dynamics in ET, presenting an equilibrium between closed/locked and open/unlocked 
conformers in its function, in which the flexible hinge region seems to have a determinant 
role [10,16–18]. In a recent report we have shown the importance of this hinge segment 
and the effect of ionic strength in ET to the non-physiological redox partner cytochrome 
c, using eight different CPR mutants targeting four critical residues [24]. Data from this 
report lead us to hypothesize a hydrogen H-bond network around R246, important for the 
function of the open/closed dynamics. 
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Although the use of the soluble surrogate redox partner cytochrome c has been 
informative, the open/closed dynamics and thus ET may occur differently with CPR’s 
natural membrane-bound electron acceptors, such as CYPs. Three hinge mutants were 
selected from our former set, namely mutant R246A, for R246’s role in the suggested H-
bond network, and mutants S243P and I245P demonstrating augmented cytochrome c 
reduction capabilities when compared with WT CPR. The CPR variants were combined 
with three different CYPs, representatives of three major CYP-families involved in drug 
metabolism. CYP families 1, 2 and 3 are responsible for 75% of all phase I metabolism 
of clinically used drugs: CYP3A4 is the major enzyme, and together these three CYPs 
are involved in almost 50% of metabolism of drugs [34]. Different experimental 
approaches were used to probe the effect of these hinge mutations. 
The first general observation is that none of the three mutations caused a complete 
inactivation of CYP activity (i.e., obliterated CPR electron transfer to CYP), consistent 
with the data obtained using cytochrome c as electron acceptor [24]. We thus confirm that 
the three targeted positions in the hinge region are certainly part of a set of residues 
capable of controlling the CPR function and thus the effects of the mutations on internal 
and external ET are partially compensated by a larger network involved in the structural 
transitions (opening/closing). 
The second interesting feature that these mutants demonstrated was their relative 
selectivity in inducing CYP-isoform dependent effects. This was first observed with CYP 
mediated bioactivation of pre-carcinogens, which seemed CYP isoform and in some cases 
substrate dependent. Still, the measurement of mutagenicity might be a quite indirect 
measurement of CYP activity, in generating DNA damaging metabolites. However, the 
specific features of CPR hinge mutants were more clearly demonstrated by the ionic 
strength dependency of CYP activities. Salt activity profiles were deviated differently by 
the three CPR hinge mutations, in a CYP-isoform dependent manner (Figures 2.7 and 
2.8). We previously demonstrated that the salt concentration at which the overall CPR to 
acceptor ET occurs depends on the relative difference in the rate of reduction of CPR and 
the rate of reduction of the electron acceptor [17]. The fact that all hinge mutations affect 
the salt concentration at which this maximal activity occur indicate that these CPR 
mutations modify the conformational equilibria. However, as noted above, all mutations 
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have distinct salt-dependent signatures (Figure 2.8). We can thus hypothesize that the 
induced differences in conformational equilibria affect differently the three tested CYPs. 
Interestingly, all Vmax and KM values measured for the three CYPs were nearly identical 
between CPR mutants. This reinforces our current hypotheses addressing the 
conformational equilibria: The single hinge CPR mutants modify the salt-dependent 
conformational equilibria and not the intrinsic CYP properties. As such, they uncover the 
dependence of CYPs toward these conformational equilibria and provide a potential 
explanation of the mechanism by which CPR could, in certain conditions, favor one CYP 
over another. 
An additional interesting feature of these salt profiles concerns the optimal salt 
concentration for CYP activity. Previously, when membrane-bound, WT CPR and the 
three mutants demonstrated very different salt concentrations for optimal cytochrome c 
reduction (ranging from 220–550 mM NaCl [24]). However, in the current study when 
combined with CYP1A2, 2A6 or 3A4, optimal activities were found at 100–200 mM 
NaCl, which together with the K/P reaction buffer approaches the ionic strength of 
physiological serum (154 mM KCl). This current data set exemplifies the difference in 
ET between the soluble surrogate electron acceptor cytochrome c and CPR’s natural 
membrane-bound redox partners. Maximum ET rates of soluble WT CPR in cytochrome 
c reduction was found to occur when CPR was equally distributed between open and 
closed conformers at approximately 375 mM NaCl [17]. With membrane bound WT 
CPR, maximum cytochrome c reduction rates were shifted above 500 mM NaCl, namely 
at 527 mM [24]. As such, data from our previous and current study suggests that optimal 
ET to various acceptors, either natural or artificial, occurs at very different ionic strengths. 
However, under physiological conditions, membrane bound CPR is present in an 
equilibrium, which is mostly in the locked state, however maintaining a very fast rate in 
alternating between open and closed conformations. This reinforce the idea that additional 
factors, such as the presence of membrane bound redox-partners, with stoichiometry’s 
favoring the electron acceptors (as is the case for CYPs, outnumbering CPR by a factor 
of 5–10), modulate the open/closed dynamics, as we put forward in our previous study 
[24]. 
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As mentioned above, our data showed differences in the salt effect of the three different 
CYPs when combined with WT CPR, corroborating the study by Yun et al. [35] that 
ascribed the ionic strength effect observed mostly to CPR:CYP “interaction” while 
having relative minor effects on CYP protein conformation [36]. Still, results of the study 
of Voznesensky and Schenkman [37] indicated that charge pairing between CPR and 
CYP may not be the major determinant of the salt effect. Our current data, as well as that 
of our previous study [24] confirms that the CPR:CYP interaction (i.e., electronic flow) 
dependency on ionic strength is mainly determined by its effect on the conformational 
equilibrium between locked and unlocked states of CPR and only in a minor manner by 
electrostatic interactions (affinity) between the FMN domain and the acceptor. Due to this 
major salt effect on CPR’s open/closed dynamics, the identification of potential 
electrostatic interactions between CPR and CYP have therefore been obscured. In 
retrospect, the seminal studies of Voznesensky and Schenkman [37,38] and of others 
(reviewed in [32]) on the salt effect of CYP catalysis in the quest for electrostatic 
interactions between CPR and CYP have been hampered by the lack of knowledge, at 
that time, on the salt-dependent protein dynamics of CPR. 
In vivo, under constant ionic strengths conditions, affinity parameters may become 
determining in the CPR:CYP interaction, modulating the open/closed dynamics as 
indicated above. CYB5, the optional electron donor, demonstrated also 
stimulation/inhibition profiles that were dependent on CYPs, as well as on the various 
CPR used. This may also sign a relatively minor role for the affinity between CPR/CYP 
and CYB5/CYP interactions. Although CPR and CYB5 share similar, but not identical, 
binding-sites on the proximal side of CYP [39], the competition between the two electron 
donors does not seem to be a major factor in controlling CYP activities. Still, subtle 
differences in electrostatic interactions between the CPR/CYP and CYB5/CYP 
complexes have been shown [40,41], which seem even to be depending on substrate 
binding [42], indicating specific features in the sampling of the ensemble of open 
conformers of CPR. 
Overall, our data point out that salt profiles are specific to CYP isoforms dependent 
interaction with CPR. The idea emerges for the existence of an ensemble of different 
unlocked CPR conformers that may be required for CYP-specific interactions. The highly 
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flexible hinge region allows for a large ensemble of open conformations from which only 
a few or a subset may be required for ET to CYPs. CPR hinge mutants, by modifying the 
conformational equilibrium (as seen in salt profiles) may either promote or hinder specific 
conformations of the unlocked state, thus allowing or preventing interactions with 
(structurally) different redox partners. Such a selection of specific open conformations 
could explain the differential effect of the three hinge mutations on the activity of the 
different CYPs. Moreover, the soluble cytochrome c will sample these conformers quite 
differently when compared with the membrane-bound CYP redox partner, a plausible 
explanation for the difference in effects of the three hinge mutants when measuring ET 
to cytochrome c [24] or CYPs (this study). 
From a structural perspective, it is clear that different CYP isoforms must share a common 
functional CPR binding surface. Although mitochondrial CYPs seem to have a signature 
of key basic amino acids on the proximal side for their interaction with the iron–sulfur 
protein adrenodoxin, such signature sequences do not exist for microsomal CYPs in their 
interaction with CPR [43]. This implies diversity in critical amino acids on their proximal 
side and suggests the possibility of affinity differences of microsomal CYPs for CPR, a 
plausible key element in the sampling of the open CPR conformers. 
The conformational plasticity of CYPs could additionally play a role in this respect. 
Substrate binding has been shown to cause (subtle) conformational changes at the 
proximal site of CYPs, reviewed in Kandel and Lampe, 2014 [33], which may influence 
the affinity and thus sampling of open conformers of CPR for effective ET. In fact, this 
seems to be corroborated by our data of the hinge mutations, causing beside CYP-isoform 
dependent seemingly also substrate dependent effects, as described above. 
It is tempting to speculate that CPR’s protein dynamics, containing different ensembles 
of closed and open conformations, was Nature’s way to enable CPR to be the 
“degenerated” electron supplier of so many (structural and functional) different redox-
partners. In this respect it would be of interest to obtain insight on the evolutionary gain 
and thus the physiological relevance of such a universal electron donor for enzymes, 
involved in some many different and crucial metabolic pathways. In parallel to other 
central enzymes, the possibility may exist of a central hub- or central controller-function 
of CPR, for the fine tuning of multiple metabolic pathways and energy (NADPH) usage. 
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2.2.5 MATERIALS AND METHODS  
 
Reagents 
L-Arginine, thiamine, chloramphenicol, ampicillin, kanamycin sulfate, isopropyl β-D-
thiogalactoside (IPTG) (dioxane-free), δ-aminolevulinic acid (δ-Ala), cytochrome c 
(horse heart), glucose 6-phosphate, glucose 6-phosphate dehydrogenase, nicotinamide 
adenine dinucleotide phosphate (NADP+ and NADPH), 2-aminoanthracene (2AA), N-
nitrosodiethylamine (NNdEA), 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), 
aflatoxin B1 (AfB1), resorufin (R), 7-hydroxy coumarine (7-OH C) and fluorescein (F) 
were obtained from Sigma-Aldrich (St. Louis, MO, USA). 2-amino-3-
methylimidazo(4,5-f)quinolone (IQ) was obtained from Toronto Research Chemicals 
(North York, ON, Canada). LB Broth (Formedium, Norfolk, UK), bacto tryptone and 
bacto peptone were purchased from BD Biosciences (San Jose, CA, USA). Bacto yeast 
extract was obtained from Formedium (Norwich, England). EthR and coumarin were 
obtained from BD Biosciences (San Jose, CA, USA) and DBF from Santa Cruz 
Biotechnology (Santa Cruz, CA, USA). A polyclonal antibody from rabbit serum raised 
against recombinant human CPR obtained from Genetex (GTX101099) (Irvine, CA, 
USA) was used for immunodetection of the membrane-bound CPR. 
 
Bacterial Expression of Human CYB5 and Purification 
The cDNA of the open reading frame of human full length CYB5 was cloned in pET15b, 
as described in Nunez et al., 2010 [44], except that the full sequence was used instead of 
only the soluble part of it. The resulting plasmid was transformed into BL21-DE3 for 
expression. A single colony was grown in Terrific Browth medium containing 100 µg/mL 
ampicillin for 72 h with shaking at 22 ºC. Cells were harvested by centrifugation at 4000x 
g, and the resulting pellet was resuspended and incubated for 30 min in 50 mM Tris-HCl, 
pH 7.4, containing 1 mM PMSF and 1 mg/mL lysozyme. Cells were lysed by sonication. 
Then 0.02 mg/mL RNase and 0.05 mg/mL DNase were added, and CYB5 was solubilized 
at 4 ºC with 1% (w/v) sodium cholate, pH 7.4, for 1 h with moderate shaking. Supernatant 
was loaded onto a DEAE-cellulose anion-exchange column equilibrated with 0.2% (w/v) 
sodium cholate, 20 mM sodium/potassium phosphate buffer, pH 7.4. CYB5 was eluted 
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with 0.5 M NaCl, 0.2% cholate, and 20 mM sodium/potassium phosphate buffer, pH 7.4. 
Fractions containing CYB5 were applied to a hydroxylapatite column equilibrated with 
0.5 M NaCl and 20 mM sodium/potassium phosphate buffer, pH 7.4. Pure CYB5 was 
eluted with 0.1% (w/v) sodium cholate and 0.5 M sodium/potassium phosphate buffer 
and dialyzed against 0.1% (w/v) sodium cholate, 1 mM PMSF, and 20 mM 
sodium/potassium phosphate buffer. CYB5 content of samples was determined by 
spectrophotometric techniques as described previously [28,29]. CYB5 was concentrated 
and stored at -20 ºC. 
 
Bacterial Co-Expression of Human CPR Mutants and CYPs 
CPR forms were expressed as a full-length membrane bound proteins using a dedicated 
E. coli host, the BTC strain, using the specialized bi-plasmid system adequate for co-
expression of CPR with representative human CYP [26,27]. Plasmid pLCM_POR [20] 
was used for the expression of the membrane-bound, full-length WT form and mutants 
of human CPR [24]. The expression of human CYP-isoforms in the cell model was 
accomplished with plasmid pCWori containing human wildtype CYP cDNA 
(pCWh_1A2, pCWh_2A6 or pCWh_3A4) [45]. The pLCM_POR and the CYP plasmids 
pCWh were transfected through standard electroporation procedures [22]. Each strain 
was cultured in TB medium supplemented with peptone (2 g/L), thiamine (1 µg/mL), 
ampicillin (50 µg/mL), kanamycin (15 µg/mL), chloramphenicol (10 µg/mL), trace 
elements solution [46] (0.4 µL/mL), IPTG (0.2 mmol/L) and δ-Ala (100 µmol/L), final 
concentrations. Cultures were started with -80 ºC glycerol stocks and cells were grown 
for 16 h at 28 ºC with moderate agitation. CYP content of bacterial whole-cells 
preparations was determined using standard CO-difference spectrophotometry [47]  
(see annex 1). 
 
Whole-Cell Mutagenicity Assays 
The mutagenicity assays were performed as described previously [20,23,45,47] using the 
liquid pre-incubation assay technique [48,49]). Briefly, BTC bacteria were grown for  
18 h in TB medium supplemented with peptone (2 g/L), thiamine (1 µg/mL), ampicillin 
(50 µg/mL), kanamycin (15 µg/mL), a mixture of trace elements solution [46]  
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(0.4 µL/mL) and IPTG (0.2 µmol/L), final concentrations. Pre-incubation was performed 
for 45 min in an orbital shaker at 37 ºC before plating. Incubation buffer contained 10 
mM glucose. Stock solutions of carcinogens were freshly made in dimethyl sulfoxide 
(DMSO) and working solutions were obtained by dilution in water. DMSO concentration 
in preincubations were ≤1.3%. Experiments were performed at least in triplicate. 
Revertant colonies on L-Arg selector plates were counted after 48 h incubation at 37 ºC. 
Revertant colonies were determined by ProtoCOL 3 colony counter (Synbiosis, 
Cambridge, UK) using ProtoCOL V0 1.0.6 Software. CYP-mediated bioactivation was 
expressed in terms of mutagenic activity [L-arginine prototrophic (revertant) colonies per 
nmole of test compound, or in revertant colonies per µmole of test compound], 
determined from the slope of the linear portion of the dose–response curve. 
 
Membrane Preparation and Characterization 
Membrane preparations were isolated as previously described [22,24]. Briefly, cultures 
were harvested at 2772x g for 20 min at 4 ºC. The pellet was resuspended in Tris-sucrose 
buffer (50 mM Tris-HCl, 250 mM sucrose, pH 7.8). Lysozyme was added to a final 
concentration of 0.5 mg/mL, EDTA (0.5 mM), phenylmethanesulfonyl fluoride (0.5 mM) 
and benzonase (12.5 U/mL). Cells were incubated on a roller bench for 30 min at 4 ºC. 
Cell lyses was performed by freezing (-80 ºC) and thawing (1 cycle) and by subsequent 
several short rounds (30 s) of low-intensity sonication, interspersed with 60 s of ice-bath 
submersion. The suspension was centrifuged at 2772x g, for 20 min at 4 ºC to eliminate 
unbroken cells. Membranes were pelleted by ultracentrifugation of the supernatant at 
100,000x g at 4 ºC for 60 min. Membranes were resuspended in TGE buffer (75 mM Tris-
HCl, 10% (v/v) glycerol, 25 mM EDTA, pH 7.5) using a Potter homogenizer and stored 
at -80 ºC. Protein concentrations were determined using the method described by 
Bradford, following the manufacturer’s protocol from Bio-Rad (San Francisco, CA, 
USA), using bovine serum albumin as the standard. CYP contents of membrane 
preparations were determined using CO-difference spectrophotometry (see annex 1). 
Membrane proteins were separated by SDS–PAGE gel electrophoresis (10% 
polyacrylamide gel) and either stained with Coomassie blue or electro-transferred to 
PVDF membranes and further processed. CPR content of membrane fractions was 
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quantified by immunodetection against a standard curve of purified human, full-length 
WT CPR, using polyclonal rabbit anti-CPR primary antibody and biotin-goat anti-rabbit 
antibody in combination with the fluorescent streptavidin conjugate (WesternDot 
625Western Blot Kit; Invitrogen, Eugene, OR, USA) (see Figure S2.2). Densitometry of 
CPR signals was performed using LabWorks 4.6 software (UVP, Cambridge, UK). 
 
CYP-Enzyme Assays 
Using membrane preparations, CYP-activities were assessed through determination of 
product formation by EthR O-deethylation (EROD; CYP1A2) (excitation 530 nm; 
emission 580 nm), coumarin 7-hydroxylation (CYP2A6) (excitation 330 nm; emission 
460 nm) or O-debenzylation of DBF (CYP3A4) (excitation 485 nm; emission 535 nm) 
[20,22,26]. Assays were performed in 96-well format with a multi-mode microtiter plate 
reader (SpectraMax®i3x, Molecular Devices, USA) using SoftMax Pro 2.0 Software. 
Experiments were conducted with 8 nM CYP1A2, 100 nM CYP2A6, and 25 nM 
CYP3A4 (final well concentrations). Reactions were performed in 100 mM potassium 
phosphate buffer (without NaCl) (pH 7.6) supplemented with 3 mM MgCl2 and an 
NADPH regenerating system (NADPH 200 µM, glucose 6-phosphate 500 µM and 
glucose 6-phosphate dehydrogenase 40 U.L-1, final concentrations). Stock solutions of 
EthR were prepared in DMSO, while coumarin and DBF were prepared in acetonitrile 
(ACN). Final solvents concentrations were maintained constant throughout the 
experiment (0.2% (v/v) DMSO or 0.1% (v/v) ACN). Product formation was followed for 
10 min at 37 ºC and rates were calculated by using a standard curve of the products. 
Reactions were performed in triplicate with substrate concentrations ranging up to 5 µM 
EthR (CYP1A2), 20 µM coumarin (CYP2A6) or 10 µM DBF (CYP3A4). Velocity data 
were plotted according to the Michaelis–Menten equation with high confidence  
(r2 > 0.95) using GraphPad Prism 5.01 Software (La Jolla, CA, USA) and kinetic 
parameters (kcat and KM) were derived [20,22,47]. Variance in data was analyzed using 
one-way ANOVA with Bonferroni’s multiple comparison tests, with 95% confidence 
interval - GraphPad Prism 5.01 Software (La Jolla, CA, USA). 
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Ionic Strength Effect 
Catalytic activity of CYP1A2, 2A6, and 3A4, sustained by WTCPR and CPR mutants, 
was assessed at various NaCl concentrations (0–1.25 M), using 5 µM EthR, 20 µM 
coumarin and 10 µM DBF, respectively, in 100 mM potassium phosphate buffer (pH 7.6), 
and NADPH regenerating system (NADPH 200 µM, glucose 6-phosphate 500 µM and 
glucose 6-phosphate dehydrogenase 40 U.L-1, final concentrations). Velocities were 
measured in triplicate in 96-well format using multi-mode microtiter plate reader 
(SpectraMax®i3x, Molecular Devices, San José, CA, USA; SoftMax Pro 2.0). Initial 
rates (picomoles of fluorescent product formed per picomoles of CYP per minute) were 
derived from the linear part of the kinetic traces using a standard curve of the respective 
products. Control experiments were conducted to assess the effect of ionic strength on the 
pH of the reaction matrix and the fluorescence of products. 
 
CYP Activity Titration with CYB5 
The CYB5 titration assay was performed in microplate format (96 wells) using the same 
enzyme assay conditions as described above (without NaCl), except substrate 
concentrations were hold constant (5 µM EthR, 20 µM coumarin or 7.5 µM DBF), 
applying a gradient of CYB5 (0–2000, 0–800 and 0–1000 nM for CYP1A2, 2A6 and 
3A4, respectively). 
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2.2.6 SUPPLEMENTARY MATERIALS 
 
 
 
 
 
 
Figure S2.2: Immuno-detection of human CPR variants in membrane preparations. 
 
  
 
 
Figure S2.3: Fluorescence of resorufin (R), 7-hydroxy coumarin (7-OH C) and fluorescein (F) 
with increasing NaCl concentrations, in panel A, B and C, respectively. 
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3.1 DISCUSSION AND CONCLUSIONS 
Despite the large number of microsomal CYP genes present in the human genome there 
is only one gene encoding CPR. The total CYP content of the human liver is estimated to 
be between 5- and 25-fold higher than that of CPR, suggesting competition and 
differential expression (Reed et al., 2011; Peterson et al., 1976; Estabrook et al., 1971). 
The fact that CPR and CYP interact “one on one” raises an important challenge: from a 
structural perspective, all the different CYP isoforms must share a “common” functional 
CPR binding surface. Indeed, several studies have proposed that the binding interaction 
between CYP and CPR takes place between the positively charged proximal surface near 
the CYP heme and the negatively charged FMN and FAD/NADPH domains of CPR, 
suggesting that CPR:CYP interaction is primarily driven by electrostatics (Bridges et al., 
1998; Shen and Strobel, 1993; Shimizu et al., 1991). Although mitochondrial CYPs seem 
to have a signature of key basic amino acids on the proximal side for their interaction 
with the iron–sulfur protein adrenodoxin, such signature sequences do not to exist for 
microsomal CYPs in their interaction with CPR (Pikuleva et al., 1999). Studies from more 
than two decades ago, demonstrated the strong dependence of CPR/CYP mediated 
catalysis on ionic strength conditions (Tamburini and Schenkman, 1986; Voznesensky 
and Schenkman, 1992; Schenkman et al., 1994; Sem and Kasper, 1995). The salt effect 
over CPR’s ET function was attributed to CPR:CYP interactions, as described two 
decades ago by Yun et al (Yun et al. 1996, 1998). Still other authors have suggested that 
hydrophobic interactions are more predominant (Voznesensky and Schenkman, 1992; 
Kenaan et al., 2011).  
More recently, CPR was demonstrated to exist both in a compact structure, allowing 
internal ET but unable to reduce external acceptors (Wang et al., 1997; Xia et al., 2011a; 
Vincent et al., 2012), and an assembly ensemble of open conformers that allow ET to 
redox partners (Hamdane et al., 2009; Aigrain et al., 2009; Ellis et al., 2009). In 2015, 
the study from Gilles Truan’s group provided a new paradigm for CPR functioning and 
domain dynamics (Frances et al., 2015). Their SAXS experiments showed a shift from 
locked (closed) to unlocked (open) CPR states as a function of salt concentration. 
Additionally, their NMR analyses showed the co-existence of these two CPR states, 
interchangeable with a rapid switch (600 s-1). Results of both these SAXS and NMR 
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experiments lead them to conclude that the ionic strength dependency of cytochrome c 
reduction by soluble CPR can be partly considered as a direct measure of the proportion 
of the locked vs. unlocked states (Frances et al., 2015).  
It was still not fully clear what factors may control CPR’s function and dynamics, 
particularly in relevant physiological conditions and with natural redox partners. The role 
of the competition between CYP isoforms for CPR and its relation to CPR’s 
conformational transitions is complex. CPR:CYP interactions were suggested to be 
influenced by many factors including CPR genetic variants, CYP isoform, availability of 
substrates, membrane anchoring, ionic strength and redox status of the flavin cofactors 
(Hlavica et al., 2003; Kranendonk et al., 2008; Marohnic et al., 2010; Moutinho et al., 
2012; Subramanian et al., 2012; Pandey and Fluck, 2013).  
The hinge segment of CPR, inserted in the LD between FAD and FMN domains, had 
already been considered of importance for conformational transitions that occur through 
a rapid swinging and rotational movement (Frances et al., 2015; Sündermann and 
Oostenbrink, 2013). Specifically, hinge residues G240 and S243 were seemingly 
involved in the large conformational changes of the protein (Aigrain et al., 2009) while 
residues I245 and R246 were considered, by an in silico molecular dynamics study, to 
form a pivot where the opening and rotational movement of the domain takes place 
(Sündermann and Oostenbrink, 2013). However, besides the suggestions of the putative 
function of these residues, little is known about the role of the hinge segment of CPR in 
the ET mechanism and in the interaction between CPR and its redox partners. Hence, the 
aim of this PhD study was to understand the role of specific residues of the hinge segment 
in the conformational equilibrium of human CPR, their role in the ionic strength effect in 
the open-closed dynamics and interaction with structural diverse redox partners, such as 
CYPs. 
The four hinge residues previously mentioned were tested for their role in the flexibility 
and ionic interactions of CPR dynamics, as described in Section 2.1. For this purpose, the 
four amino acids were substituted by alanine or proline, with the aim of modifying either 
the flexibility and/or the potential ionic interactions of the hinge segment of CPR. The 
effect of each these hinge mutations were studied both when CPR was soluble (i.e. lacking 
the N-terminal membrane anchoring section) or membrane-bound (full-length), to obtain 
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clues on the interaction with its redox-partners. Work described in this section focused 
on the effect of reduction of the frequently used, although soluble, surrogate substrate 
cytochrome c (Campelo et al., 2017). 
Reduction of cytochrome c by these CPR hinge mutants and WT form was measured at 
different salt concentrations, to assess the role of ionic strength in CPR’s dynamics and 
its ET function. Introduced mutations had pronounced effects either on the 
conformational equilibrium or the ET efficiency. Yet, all the mutants remained active: 
i.e. all mutants were found capable of reducing cytochrome c, although with different 
efficiencies. Maximal rates of cytochrome c reduction were shifted to lower salt 
concentration, in comparison to WT CPR, which means that generated mutants had 
greater tendency to favor the unlocked state, regardless of the presence or absence of the 
membrane. Data seem to indicate that the targeted positions are part of a larger network 
of structural determinants controlling the conformational exchange between the locked 
and unlocked state of CPR. Based on the research outcome described in this section a salt 
bridge network at the interface of the hinge and the connecting domain was hypothesized 
with a central role of residue R246.  
The studies with CPR hinge mutants sustaining cytochrome c reduction showed that the 
effects of CPR mutations, although similar for some, were specifically different when 
present in the soluble or membrane-bound context. In particular, data of mutations of 
residues S243 and I245 seemed to indicate that these two residues are of importance for 
the open/closed dynamics of membrane anchored CPR. The N-terminal hydrophobic 
anchoring sequence of CPR had previously been suggested to establish hydrophobic 
interactions with the membrane domains of CYPs, of importance for a productive 
alignment of CPR with its redox-partners to support a successful ET (Hlavica et al., 2003; 
Kandel and Lampe, 2014). The rate limiting steps might not be equivalent between the 
soluble and membrane bound form, which suggested a role of the membrane anchoring 
and hydrophobicity in the activity and dynamics of CPR (Campelo et al., 2017). 
In the interaction with cytochrome c, the velocity data of the CPR hinge mutants 
confirmed that the electrostatic and flexibility properties of the hinge segment are 
important conformational factors in CPR’s function (Campelo et al., 2017). However, 
cytochrome c, although frequently used as surrogate substrate, is a soluble and non-
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physiological redox partner of CPR. Although informative, the use of cytochrome c might 
have obscured important clues for CPR’s ET with membrane-bound natural redox 
partners as CYPs, which is thought to be of importance as described above.  
Drug-metabolizing CYPs have a promiscuous nature (Davydov and Helpert, 2008; Atkins 
et al., 2006) and can be susceptible to functional variation due to CPR mutations (Fluck 
et al., 2010; Agrawal et al., 2010; Chen et al., 2012). Some polymorphic CPR variants as 
well as several rare variants found in patients with POR deficiency (Antley Bixler 
Syndrome), were previously shown to express themselves in the form of alterations in the 
isoform dependent CYP-mediated metabolism of certain substrates (Huang et al., 2005; 
Huang et al., 2008; Kranendonk et al., 2008; Xia et al., 2011b; Moutinho et al., 2012; 
Pandey and Fluck, 2013; McCammon et al., 2016). Small structural changes, such as a 
single amino acid substitution, could have dramatic functional consequences on the 
ability of CPR to efficiently deliver its electrons to a particular CYP isoform. In a study 
examining the effect of the 35 most common (polymorphic) CPR mutations, Miller and 
colleagues could show that while most mutations either decreased CYP activity or 
eliminated activity all together, other mutations enhanced CYP activity (Agrawal et al., 
2010). It is clear that there are important functional consequences for subtle alterations in 
the interactions between CPR and CYP isoforms (Kandel and Lampe, 2014), although 
the mechanisms behind these consequences are still unknown.  
Research described in Section 2.2 addresses this issue specifically. A selection of the 
former described CPR hinge mutants of Section 2.1, were tested with three CYPs 
isoforms (1A2, 2A6 and 3A4), representative for three major human drug-metabolizing 
CYP enzyme families. Three membrane-bound CPR hinge mutants were used, namely 
mutant R246A, for its role in H-bond network, and mutants S243P and I245P for 
presenting augmented cytochrome c reduction when compared to WT CPR. The role of 
these hinge residues in CPR interaction with different CYP were probed using different 
approaches (Campelo et al., 2018). Most interestingly, the three CPR hinge mutants 
demonstrated differential effects which were CYP-isoform and seemingly substrate 
dependent. The results clearly demonstrated, that each CYP interacts with CPR in a 
unique manner, according to specific structural requisites that allow CPR:CYP 
interactions and the formation of specific and productive ET complexes. It is shown that 
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the “salt” effect observed in CPR:CYP interaction and CPR’s ET function, is mainly 
determined by its effect on the conformational equilibrium of CPR and only in a minor 
manner by electrostatic interactions between the FMN domain and the CPR’s redox 
partner (Campelo et al., 2018). More importantly, the obtained data suggests that the 
highly flexible hinge of CPR is responsible for the existence of a conformational 
aggregate of different open CPR conformers, suggesting an underlying mechanism 
enabling ET-interaction with structural varied redox partners. This can additionally 
explain that subtle structural deviations in CPR as found in the human population, might 
have CYP isoform specific effects, as described above. 
The precise way by which CPR interacts with all structural different microsomal CYPs 
for ET, and how each of these redox partners probes the ensemble of CPR’s open 
conformers and also what mechanisms guide the protein-protein interactions that are at 
play within CYP enzyme complex are still matters to be further clarified. It has been 
shown that basic residues in CYP form a positive electrostatic ring that steers the docking 
site near the heme to a negatively charged patch on CPR at the FMN domain (Rwere et 
al., 2016). The degenerated signature of CYP-surface amino acids at the CPR-binding 
interface suggests that CPR interacts with microsomal CYPs in an isoform dependent 
manner, which was shown with our studies on the hinge segment of CPR, as described in 
Section 2.2 (Campelo et al., 2018). Differential affinity parameters of microsomal CYPs 
for CPR may be a key element in the assembling of CPR with specific CYP-isoforms. In 
our laboratory, studies are currently being conducted with the aim of modifying CPR’s 
FMN-domain residues for increased activity of specific CYP-isoforms, i.e. to specialize 
CPR for interaction with a specific redox partner. This will allow the identification of 
structural requisites of the FMN domain of CPR, responsible for “degenerated” 
interactions with its structural diverse redox partners. 
CPR has other natural redox partners besides CYPs, such as HO, that were not subject of 
this PhD research. CPR’s structural requisites with different redox partners might not be 
equivalent to those with CYPs’ (Higashimoto et al., 2005). To complete a cycle of the 
HO reaction, HO consumes seven electrons provided by CPR whereas CYPs consume 
only two electrons (Sugishima et al., 2014). Sugishima and colleagues showed that the 
open-closed mechanism proposed for ET from CPR to CYP also occurs  
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with HO (Sugishima et al., 2014), reinforcing the notion that the open-closed dynamics 
is an integral part of CPR’s capacity in sustaining activity of structural diverse redox 
partners. However, unlike CYPs, electrons are proposed to be supplied by CPR through 
interaction with HO, involving the binding of the phosphate moiety of NADP+/NADPH, 
bound to CPR (Wang and de Montellano, 2003; Pandey et al., 2010). Studies by Pandey 
and colleagues have shown that mutations in CPR identified from patients with POR 
deficiency lead to reduced HO activities. Further analysis of additional genetic variants 
of CPR may also lead to the identification of specific target proteins, including CYPs and 
HO that are affected by CPR variants (Pandey et al., 2010). 
Finally, CPR may function as a model for diflavin protein reductase and for other 
multidomain redox systems such as nitric-oxide synthase, methionine synthase reductase, 
dihydropyrimidine dehydrogenase, NADPH-dependent diflavin oxidoreductase 1 
(Lienhart et al., 2013). That is in particular the case for a novel human dual flavin 
reductase, that was found overexpressed in cancers and may play a role in the metabolic 
activation of bioreductive anticancer drugs and other chemicals activated by one-electron 
reduction (Paine et al., 2000). 
Results described in this thesis assisted in further clarifying the precise control of the 
catalytic cycle of CPR and other diflavin reductases, the coupling with their redox 
partners and its involvement in relevant human physiological pathways. 
 
  
3. DISCUSSION AND CONCLUSIONS 
121 
 
3.2 REFERENCES 
Agrawal V, Choi JH, Giacomini KM, Miller WL. Substrate-specific modulation of 
CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase. 
Pharmacogenet Genomics. 2010; 20(10): 611-8. DOI: 10.1097/FPC.0b013e32833 
e0cb5. 
Aigrain L, Pompon D, Moréra S, Truan G. Structure of the open conformation of a 
functional chimeric NADPH cytochrome P450 reductase. EMBO Rep. 2009; 10(7): 
742-7. DOI: 10.1038/embor.2009.82. 
Atkins WM. Current views on the fundamental mechanisms of cytochrome P450 
allosterism. Expert Opin Drug Metab Toxicol. 2006; 2(4): 573-9. DOI: 10.1517/ 
17425255.2.4.573. 
Bridges A, Gruenke L, Chang YT, Vakser IA, Loew G, Waskell L. Identification of the 
binding site on cytochrome P450 2B4 for cytochrome b5 and cytochrome P450 
reductase. J Biol Chem. 1998; 273(27): 17036-49. 
Campelo D, Esteves F, Brito Palma B, Costa Gomes B, Rueff J, Lautier T, Urban P, Truan 
G, Kranendonk M. Probing the Role of the Hinge Segment of Cytochrome P450 
Oxidoreductase in the Interaction with Cytochrome P450. Int J Mol Sci. 2018; 19(12). 
DOI: 10.3390/ijms19123914. 
Campelo D, Lautier T, Urban P, Esteves F, Bozonnet S, Truan G, Kranendonk M. The 
Hinge Segment of Human NADPH-Cytochrome P450 Reductase in Conformational 
Switching: The Critical Role of Ionic Strength. Front Pharmacol. 2017; 8: 755. DOI: 
10.3389/fphar.2017.00755.  
Chen X, Pan LQ, Naranmandura H, Zeng S, Chen SQ. Influence of various polymorphic 
variants of cytochrome P450 oxidoreductase (POR) on drug metabolic activity of 
CYP3A4 and CYP2B6. PLoS One. 2012; 7(6): e38495. DOI: 10.1371/ 
journal.pone.0038495.  
Davydov DR, Halpert JR. Allosteric P450 mechanisms: multiple binding sites, multiple 
conformers or both? Expert Opin Drug Metab Toxicol. 2008; 4(12): 1523-35. DOI: 
10.1517/17425250802500028. 
  
3. DISCUSSION AND CONCLUSIONS 
122 
 
Ellis J, Gutierrez A, Barsukov IL, Huang WC, Grossmann JG, Roberts GC. Domain 
motion in cytochrome P450 reductase: conformational equilibria revealed by NMR 
and small-angle x-ray scattering. J Biol Chem. 2009; 284(52): 36628-37. DOI: 10. 
1074/jbc.M109.054304. 
Estabrook RW, Hildebrandt AG, Baron J, Netter KJ, Leibman K. A new spectral 
intermediate associated with cytochrome P-450 function in liver microsomes. 
Biochem. Biophys. Res. Commun. 1971; 42: 132−139. 
Flück CE, Mullis PE, Pandey AV. Reduction in hepatic drug metabolizing CYP3A4 
activities caused by P450 oxidoreductase mutations identified in patients with 
disordered steroid metabolism. Biochem Biophys Res Commun. 2010; 401(1): 149-
53. DOI: 10.1016/j.bbrc.2010.09.035.  
Frances O, Fatemi F, Pompon D, Guittet E, Sizun C, Pérez J, Lescop E, Truan G. A well-
balanced preexisting equilibrium governs electron flux efficiency of a multidomain 
diflavin reductase. Biophys J. 2015; 108(6): 1527-1536. DOI: 10.1016/ 
j.bpj.2015.01.032. 
Hamdane D, Xia C, Im SC, Zhang H, Kim JJ, Waskell L. Structure and function of an 
NADPH-cytochrome P450 oxidoreductase in an open conformation capable of 
reducing cytochrome P450. J Biol Chem. 2009; 284(17): 11374-84. DOI: 10.1074/ 
jbc.M807868200. 
Higashimoto Y, Sakamoto H, Hayashi S, Sugishima M, Fukuyama K, Palmer G, Noguchi 
M. Involvement of NADPH in the interaction between heme oxygenase-1 and 
cytochrome P450 reductase. J Biol Chem. 2005; 280(1): 729-37. DOI: 10.1074/ 
jbc.M406203200. 
Hlavica P, Schulze J, Lewis DF. Functional interaction of cytochrome P450 with its redox 
partners: a critical assessment and update of the topology of predicted contact regions. 
J Inorg Biochem. 2003; 96(2-3): 279-97. 
Huang N, Agrawal V, Giacomini KM, Miller WL. Genetics of P450 oxidoreductase: 
sequence variation in 842 individuals of four ethnicities and activities of 15 missense 
mutations. Proc Natl Acad Sci USA. 2008; 105(5): 1733-8.  
  
3. DISCUSSION AND CONCLUSIONS 
123 
 
Huang N, Pandey AV, Agrawal V, Reardon W, Lapunzina PD, Mowat D, Jabs EW, Van 
Vliet G, Sack J, Flück CE, Miller WL. Diversity and function of mutations in P450 
oxidoreductase in patients with Antley-Bixler syndrome and disordered 
steroidogenesis. Am J Hum Genet. 2005; 76(5): 729-49. DOI: 10.1073/pnas. 
0711621105. 
Kandel SE, Lampe JN. Role of protein-protein interactions in cytochrome P450-mediated 
drug metabolism and toxicity. Chem Res Toxicol. 2014; 27(9): 1474-86. DOI: 
10.1021/tx500203s. 
Kenaan C, Zhang H, Shea EV, Hollenberg PF. Uncovering the role of hydrophobic 
residues in cytochrome P450- cytochrome P450 reductase interactions. Biochemistry 
2011; 50(19): 3957−3967. DOI: 10.1021/bi1020748. 
Kranendonk M, Marohnic CC, Panda SP, Duarte MP, Oliveira JS, Masters BS, Rueff J. 
Impairment of human CYP1A2-mediated xenobiotic metabolism by Antley-Bixler 
syndrome variants of cytochrome P450 oxidoreductase. Arch Biochem Biophys. 2008; 
475(2): 93-9. DOI: 10.1016/j.abb.2008.04.014. 
Lienhart WD, Gudipati V, Macheroux P. The human flavoproteome. Arch Biochem 
Biophys. 2013; 535(2): 150-62. DOI: 10.1016/j.abb.2013.02.015. 
Marohnic CC, Panda SP, McCammon K, Rueff J, Masters BS, Kranendonk M. Human 
cytochrome P450 oxidoreductase deficiency caused by the Y181D mutation: 
molecular consequences and rescue of defect. Human Drug Metab Dispos. 2010; 
38(2): 332-40. DOI: 10.1124/dmd.109.030445. 
McCammon KM, Panda SP, Xia C, Kim JJ, Moutinho D, Kranendonk M, Auchus RJ, 
Lafer EM, Ghosh D, Martasek P, Kar R, Masters BS, Roman LJ. Instability of the 
Human Cytochrome P450 Reductase A287P Variant Is the Major Contributor to Its 
Antley-Bixler Syndrome-like Phenotype. J Biol Chem. 2016; 291(39): 20487-502. 
DOI: 10.1074/jbc.M116.716019. 
Moutinho D, Marohnic CC, Panda SP, Rueff J, Masters BS, Kranendonk M. Altered 
human CYP3A4 activity caused by Antley-Bixler syndrome-related variants of 
NADPH-cytochrome P450 oxidoreductase measured in a robust in vitro system. Drug 
Metab Dispos. 2012; 40(4): 754-60. DOI: 10.1124/dmd.111.042820. 
Murataliev MB, Feyereisen R, Walker FA. Electron transfer by diflavin reductases. 
Biochim Biophys Acta. 2004; 1698(1): 1-26. DOI: 10.1016/j.bbapap.2003.10.003. 
3. DISCUSSION AND CONCLUSIONS 
124 
 
Paine MJ, Garner AP, Powell D, Sibbald J, Sales M, Pratt N, Smith T, Tew DG, Wolf 
CR. Cloning and characterization of a novel human dual flavin reductase. J Biol Chem. 
2000; 275(2): 1471-8. 
Pandey AV, Flück CE, Mullis PE. Altered heme catabolism by heme oxygenase-1 caused 
by mutations in human NADPH cytochrome P450 reductase. Biochem Biophys Res 
Commun. 2010; 400(3): 374-8. DOI: 10.1016/j.bbrc.2010.08.072.  
Pandey AV, Flück CE. NADPH P450 oxidoreductase: structure, function, and pathology 
of diseases. Pharmacol Ther. 2013; 138(2): 229-54. DOI: 10.1016/j. 
pharmthera.2013.01.010. 
Peterson JA, Ebel RE, O'Keeffe DH, Matsubara T, Estabrook RW. Temperature 
dependence of cytochrome P-450 reduction. A model for NADPH-cytochrome P-450 
reductase:cytochrome P-450 interaction. J Biol Chem. 1976; 251(13): 4010-6. 
Pikuleva IA, Cao C, Waterman MR. An additional electrostatic interaction between 
adrenodoxin and P450c27 (CYP27A1) results in tighter binding than between 
adrenodoxin and P450scc (CYP11A1). J Biol Chem. 1999; 274(4): 2045-52. 
Reed JR, Cawley GF, Backes WL. Inhibition of cytochrome P450 1A2-mediated 
metabolism and production of reactive oxygen species by heme oxygenase-1 in rat 
liver microsomes. Drug Metab Lett. 2011; 5(1): 6-16. 
Rwere F, Xia C, Im S, Haque MM, Stuehr DJ, Waskell L, Kim JJ. Mutants of Cytochrome 
P450 Reductase Lacking Either Gly-141 or Gly-143 Destabilize Its FMN 
Semiquinone. J Biol Chem. 2016; 291(28): 14639-61. DOI: 10.1074/jbc. 
M116.724625.  
Schenkman JB, Voznesensky AI, Jansson I. Influence of ionic strength on the P450 
monooxygenase reaction and role of cytochrome b5 in the process. Arch Biochem 
Biophys. 1994; 314(1): 234-41. DOI: 10.1006/abbi.1994.1435 
Sem DS, Kasper CB. Effect of ionic strength on the kinetic mechanism and relative rate 
limitation of steps in the model NADPH-cytochrome P450 oxidoreductase reaction 
with cytochrome c. Biochemistry. 1995; 34(39): 12768-74. 
Shen S, Strobel HW. Role of lysine and arginine residues of cytochrome P450 in the 
interaction between cytochrome P4502B1 and NADPH-cytochrome P450 reductase. 
Arch Biochem Biophys. 1993; 304(1): 257-65. 
3. DISCUSSION AND CONCLUSIONS 
125 
 
Shimizu T, Tateishi T, Hatano M, Fujii-Kuriyama Y. Probing the role of lysines and 
arginines in the catalytic function of cytochrome P450d by site-directed mutagenesis. 
Interaction with NADPH-cytochrome P450 reductase. J Biol Chem. 1991; 266(6): 
3372-5. 
Subramanian M, Agrawal V, Sandee D, Tam HK, Miller WL, Tracy TS. Effect of P450 
oxidoreductase variants on the metabolism of model substrates mediated by 
CYP2C9.1, CYP2C9.2, and CYP2C9.3. Pharmacogenet Genomics. 2012; 22(8): 590-
7. DOI: 10.1097/FPC.0b013e3283544062. 
Sugishima M, Sato H, Higashimoto Y, Harada J, Wada K, Fukuyama K, Noguchi M. 
Structural basis for the electron transfer from an open form of NADPH-cytochrome 
P450 oxidoreductase to heme oxygenase. Proc Natl Acad Sci U S A. 2014; 111(7): 
2524-9. DOI: 10.1073/pnas.1322034111. 
Sündermann A, Oostenbrink C. Molecular dynamics simulations give insight into the 
conformational change, complex formation, and electron transfer pathway for 
cytochrome P450 reductase. Protein Sci. 2013; 22(9): 1183-95. DOI: 10.1002/pro. 
2307. 
Tamburini PP, Schenkman JB. Differences in the mechanism of functional interaction 
between NADPH-cytochrome P-450 reductase and its redox partners. Mol Pharmacol. 
1986; 30(2): 178-85. 
Vincent B, Morellet N, Fatemi F, Aigrain L, Truan G, Guittet E, Lescop E. The closed 
and compact domain organization of the 70-kDa human cytochrome P450 reductase 
in its oxidized state as revealed by NMR. J Mol Biol. 2012; 420(4-5): 296-309. DOI: 
10.1016/j.jmb.2012.03.022. 
Voznesensky AI, Schenkman JB. The cytochrome P450 2B4-NADPH cytochrome P450 
reductase electron transfer complex is not formed by charge-pairing. J Biol Chem. 
1992; 267(21): 14669-76. 
Wang J, de Montellano PR. The binding sites on human heme oxygenase-1 for 
cytochrome P450 reductase and biliverdin reductase. J Biol Chem. 2003; 278(22): 
20069-76. DOI: 10.1074/jbc.M300989200. 
Wang M, Roberts DL, Paschke R, Shea TM, Masters BS, Kim JJ. Three-dimensional 
structure of NADPH-cytochrome P450 reductase: prototype for FMN- and FAD-
containing enzymes. Proc Natl Acad Sci U S A. 1997; 94(16): 8411-6. 
3. DISCUSSION AND CONCLUSIONS 
126 
 
Xia C, Hamdane D, Shen AL, Choi V, Kasper CB, Pearl NM, Zhang H, Im SC, Waskell 
L, Kim JJ. Conformational changes of NADPH-cytochrome P450 oxidoreductase are 
essential for catalysis and cofactor binding. J Biol Chem. 2011a; 286(18): 16246-60. 
DOI: 10.1074/jbc.M111.230532. 
Xia C, Panda SP, Marohnic CC, Martásek P, Masters BS, Kim JJ. Structural basis for 
human NADPH-cytochrome P450 oxidoreductase deficiency. Proc Natl Acad Sci U S 
A. 2011b; 108(33): 13486-91. DOI: 10.1073/pnas.1106632108. 
Yun, C. H.; Ahn, T.; Guengerich, F. P. Conformational change and activation of 
cytochrome P450 2B1 induced by salt and phospholipid. Arch Biochem Biophys. 
1998; 356(2): 229-38, DOI: 10.1006/abbi.1998.0759. 
Yun, C. H.; Song, M.; Ahn, T., Kim, H. Conformational change of cytochrome P450 1A2 
induced by sodium chloride. J Biol Chem. 1996; 271(49): 31312-6. 
 
 
  
 
4.  ANNEXES 
 
  
4. ANNEXES 
128 
 
CONTENT 
 
4.1. ANNEX 1: Experimental Procedures and optimization of protocols 
4.1.1. Generation of CPR hinge domain mutants  
4.1.2. Bacterial expression of membrane-bound forms of human CPR variants 
4.1.3. Optimization of CYP expression 
4.1.4. Optimization of E. coli membrane isolation 
4.1.5. Optimization of cytochrome c reduction assay 
 
4.2. REFERENCES 
 
  
4. ANNEXES 
129 
 
4.1 ANNEX 1: Experimental Procedures and optimization of protocols 
4.1.1 Generation of CPR hinge domain mutants  
CPR variants (alanine and proline substitutions) of hinge residues G240, S243, I245 and 
R246 were obtained using different approaches. The alanine substitution mutants, 
targeting residues I245 and R246, were obtained through standard site-directed 
mutagenesis (Phusion Site-Directed Mutagenesis Kit, Thermo Fisher Scientific) using 
specific PCR primers (Table 4.1), and the sub-cloning vector pUC_POR containing the 
initial section (1-1269 bp) of human POR cDNA encoding the FMN domain. The segment 
of the mutated human POR gene was then obtained through a EcoRI+AatII preparative 
digestion, its purification (GeneJET Gel Extraction kit, Thermo Fisher Scientific) and 
cloning into the CPR expression vector pLCM_POR (Rapid DNA Ligation kit, Thermo 
Fisher Scientific), followed by transformation into DH5α competent E. coli cells, 
prepared in our laboratory by standard protocol. The proline substitution mutants, were 
generated in the laboratory of Gilles Truan by introduction of relevant mutations in the 
cDNA encoding a human soluble CPR form (i.e. contains a N-terminal deletion of amino 
acids 1-44), present in vector pET15b. The proline substitution mutations were sub-
cloned in the pUC_POR, using Megaprimer PCR procedure of the whole pET15b_CPR 
plasmid (MEGAWHOP) (Miyazaki and Takenouchi, 2002) (for used primers, see Table 
4.2). The DNA segment containing the mutated human POR cDNA was then obtained 
through a Eco81I+SacI preparative digestion (GeneJET Gel Extraction Kit, Thermo 
Fisher Scientific) and cloned into the CPR expression vector pLCM_POR (Rapid DNA 
Ligation kit, Thermo Fisher Scientific), followed by transformation into DH5α competent 
E. coli cells as described above. All plasmidic DNA fragments of interest were extracted 
and purified (GeneJET plasmid Miniprep Kit, Thermo Fisher Scientific). The POR cDNA 
of all mutant pLCM_POR plasmids was confirmed by extensive direct Sanger sequencing 
(StabVida®) of the POR cDNA, for which four appropriate primers were used (see Table 
4.3). The chromatograms were analysed using FinchTV v1.4.0 software (Geospiza Inc.® 
2006) and sequences were aligned using dedicated software (Clustal Omega Multiple 
Sequence Alignment Tool, Analysis Tool Web Services from the EMBL-EBI 2013 and 
MultAlin Multiple sequence alignment by F. Corpet, 2000). After sequence confirmation, 
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large plasmidic DNA isolations were performed (ZymoPURE™ Plasmid Midiprep Kit, 
Zymo Research). 
 
Table 4.1: Primers used for site-directed mutagenesis.  
Primer 
1 
CPR sequence 5’ – 3’ 
Length 
(nt) 
Tm 
(ºC) 
Aminoacid 
Substitution 
Fw 1 GCGCGCCAGTACGAGCTTGTGGTCC 25 72,2 I245A 
Fw 2 GCGCAGTACGAGCTTGTGGTCCACACC 27 71,0 R246A 
Fw 3 GCGGCGCAGTACGAGCTTGTGGTCCACACC 30 71,0 I245A – R246A 
Fw 4 CGCATTCAGTACGAGCTTGTGGTC 24 70,9 I245R – R246I 
Rev 1 gctggactcctcgccagtgg 20 72,1  
Rev 2 aatgctggactcctcgccagtg 22 72,0  
1 Forward primer (Fw) 1, 3 and 4 were used with reverse primer Rev 1; Primer Fw 2 was used with Rev 2. 
Mutated nucleotides for amino acid change are highlighted in grey. 
 
 
Table 4.2: Primers for MEGAWHOP. 
Primer Sequence 5’- 3’ 
Fw CAGACATTGACCTCCTCTGTCAGAG 
Rv gacgagagcagagtcgttggctgg 
 
 
Table 4.3: Primers used for sequencing. 
Primer Sequence 5’- 3’ Tm (ºC) 
F1 CTGCCGCCAGGCAAATTCTG 56 
F2 CGGCGGGTTGGTGATGTCCA 58 
R1 AACCAGCTGGGCAAAATCCT 52 
R2 AATTCTAATGGGAGACTCCC 50 
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4.1.2 Bacterial expression of membrane-bound forms of human CPR 
variants 
CPR hinge variants were engineered and cloned in pLCM_POR, part of the bi-plasmid 
co-expression system of human CYP-competent bacterial cell model, E. coli BTC, 
previously developed for co-expression of human CPR and CYPs (Figure 1.6) (Duarte et 
al., 2005). The different pLCM_POR expression vectors containing the cDNA of each of 
the CPR mutants were combined separately with one of the E. coli expression (pCWori) 
vectors (Kranendonk et al., 1999). The pCWori vector, part of the bi-plasmid co-
expression system has been used to co-express the different isoforms of representative 
human CYP involved in drug metabolism, namely CYP1A2 2A6, or 3A4. The mock-
plasmid pCWΔ (i.e. not containing cDNA of any CYP) was used as control. The BTC 
bacteria were transfected simultaneously with each of the pLCM_POR and each of the 
pCW-vectors through electroporation (BioRad-gene pulser: 25 µF, 200 Ω, 1,35 kV) 
(Moutinho et al., 2012). Plasmid maintenance and stability was verified by analysis of 
pDNA (extraction through GeneJET Plasmid Miniprep Kit, Thermo Fisher Scientific), 
after linearization with EcoRI (single-cut restriction enzyme) and confirmed by agarose 
gel electrophoresis. All BTC strains were verified for the correct phenotype, as described 
in Table 4.4.  
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Table 4.4: Phenotypic markers of BTC strain. 
Trait 
 
Test  
Incubation 
(37ºC) 
 
Description 
 
References 
Mutation rfa- 
 
MacConkey 
agar plate 
32 h 
 Mutation in the rfa operon originates a deficient 
lipopolysaccharide core (LPSd), leading to an increased 
permeability of the cell wall and consequently 
penetration of voluminous compounds  
Fralick and Burns-Keliher, 
1994 
Kranendonk et al., 2000 
Mutation ogt- 
 
LB antibiotic 
plate 
16 h 
 DNA repair gene ogt is inactivated by transposon 
insertion to increase sensitivity to alkylating agents. The 
mutation confers resistance to chloramphenicol  
Duarte et al., 2005 
Auxotrophy 
for L-arginine 
 M9 Arg +/- 
plate 
48 h 
 
The genetic target of this E. coli strain is the auxotrophy 
of arginine. This can be reversed to prototrophy by base 
substitution (transitions/transversions) (DNA damage)  
 
Kranendonk et al., 1996 
Kranendonk et al., 1998 
Duarte et al., 2005 
Sensitivity for 
Mutagenicity 
detection 
 Mutagenicity 
test with 
4NQO 
 
Plasmid 
maintainance 
 LB antibiotic 
plate 
16 h 
 kanamycin and ampicillin resistance conveyed by 
plasmid pLCM and pCWhCYP, respectively 
Kranendonk et al., 1998 
 
 
4.1.3 Optimization of CYP expression 
To obtain optimized CYP/CPR expression in the BTC cell model, multiple culture 
conditions were verified and optimized (Table 4.5).  
 
Table 4.5: Tested parameters for culture growth/expression induction. 
Parameter Range tested 
Molarity and pH of TB buffer of TB culture medium  
(CYP isoform dependent) 
pH 6.4, 6.8, 7.0, 7.2, 7.4, 7.5, 7.6; Molarity 0.9, 1 M 
Starter Culture/Inoculum/pre-culture (volume) 100, 150, 200, 250 µL/per 25 mL of induction culture 
Induction level (IPTG) 0.05; 0.1; 0.2;0.25; 0.3 mM 
Level of δ-Ala (heme percursor) 0, 10, 25, 50, 100 uM 
Culture Temperature  27, 28 ºC 
Container (Aeration/agitation) Glass / polycarbonate; lid / no lid; 130, 150, 175 rpm 
Culture growth time  12, 13, 14, 15, 16, 18, 20, 22, 24, 25, 40, 48 h 
 
4. ANNEXES 
133 
 
CYP expression was determined through CO difference spectrophotometry using both 
whole bacterial cells and corresponding membrane preparations (Moutinho et al., 2012), 
with several modifications. Procedure was optimized to increase sensitivity and accuracy. 
Cultures were concentrated (3 x) leading to optical densities of OD 600 nm ≈ 21. Sodium 
dithionite was added (1 mg/mL, final concentration) prior to the initial scan. When using 
membrane preparations, improvement in quantification of the 450 nm absorption, was 
obtained by baseline adjustment (Amplitude of CYP peak = A450 - A436 - 0,412 x (A470 - 
A436)), based on spectral intercepts before (438 nm) and after (470 nm) the 450 nm peak 
(Figure 4.1) (Johnston et al., 2008; Johnston and Gillam, 2013). This approach reduced 
variation between replicate measurements of samples by modeling the baseline distortion 
as linear in the spectral region directly under the 450 nm absorption peak. 
 
 
 
 
 
 
 
 
 
Figure 4.1: Baseline correction (at 436 and 470 nm) indicated by dotted lines (Johnston et al., 
2008). 
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4.1.4 Optimization of E. coli membrane isolation 
Several parameters for isolation of bacterial membrane preparations were optimized, 
including sonication, centrifugation, precipitation and homogenization steps (Table 4.6). 
The formerly applied procedure, includes a relative long and high-speed centrifugation 
of the bacterial cell lysate (1h, 100k x g). This leads to a compact membrane pellet which 
is tedious to homogenize, using Potter homogenizer (Heidolph RZR-1). An alternative 
method was tested, used by collaborators of Dr. Gilles Truan in Toulouse for isolation of 
yeast microsomes. This protocol is based on an initial precipitation of the membrane 
fragments of whole cell lysate using NaCl (153 mM) and PEG-4000 (10%), with a 
subsequent shorter and relative low speed centrifugation (9k x g). Membrane pellets 
obtained with this procedure are less compact facilitating pellet homogenization. The new 
method and the former one were compared by assessing CYP- and CPR- contents and 
CYP activities. The CYP enzyme activity showed no interference by the use of NaCl and 
PEG-400 in kinetic parameters (kcat and KM). However, the total protein content (using 
the Bradford method with BSA as standard), showed consistently significant differences 
between the two methods. More importantly, semi-quantitative immune-detection of CPR 
in the membrane preparations of the new procedure showed considerable discrepancies 
with those obtained when CPR contents were determined based on cytochrome c 
reduction activity. This indicated an interference of a component of the new protocol, 
which could not be identified. Hence, the former method was maintained (Campelo et al., 
2018). 
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Table 4.6: Tested methods for membrane preparation. 
Method 
 Tested 
Parameters 
Principal Step  Result References 
Bacteria 
 
 
Sonication1, 
centrifugation2, 
precipitation and 
homogenization 
Long (1 h) and high-speed 
(100 k x g) centrifugation of 
the whole cell lysate) 
 
A compact membrane 
pellet difficult to 
homogenize 
Palma et al., 2010 
Campelo et al., 2018 
Yeast  
 Precipitation with NaCl (153 
mM) and PEG-4000 (10%) 
followed by a short (15 min) 
and low speed (9k x g) 
centrifugation  
 
Less compact pellet, 
easily homogenized / 
Interference of a non-
identified component 
Urban et al., 1990 
Cullin and Pompon, 1988 
Pompon, 1988 
1 The following homogenizers were tested: Bullet Blender 50 DX (Integrated Scientific Solutions), Vibra-
Cell VCX-500 Ultrasonic Processor (Sonics) and Sonopuls HD2070 (Bandelin). 2 For centrifugation step 
the following centrifuges were used: Beckman Optima L-100XP and Beckman L7-55. 
 
 
4.1.5 Optimization of cytochrome c reduction assay 
The cytochrome c reduction assay as used for the work described in Section 2.1 (Campelo 
et al., 2017), was performed in microplate format. For this purpose, the standard cuvette 
procedure was adapted and optimized for microplate format. Electron-transfer activity of 
CPR is based on the measurement of the absorbance increase at 550 nm (Spec UV-
2401PC, Shimadzu) when cytochrome c is reduced. Standardly, the reaction is followed 
in time (typically for 1 min) in a reaction mixture containing 50 µM cytochrome c and 
200 µM NADPH (Shet et al., 1993, Kranendonk et al., 2008) in micro cuvette format 
(reaction volume: 1 mL). To increase through-put in cytochrome c reduction detection 
for application to test different ionic strength conditions, a micro-plate format of this 
method was established, together with colleagues from Toulouse (working with the 
soluble variants of the CPR hinge mutants). For this purpose, the reaction buffers used in 
Lisbon and Toulouse were checked and compared, still using the micro cuvette format, 
namely: 
1) “Lisbon” buffer: 50 mM Tris HCl (pH 7.5), 10 mM MgCl2, 150 mM KCl, 2 mM NaN3, 
with or without the standardly used detergent (0,04% Triton X-100);  
2) “Toulouse” buffer: 20 mM Tris-HCl, 2 mM NaN3 with or without inclusion of 372 
mM NaCl - optimum salt concentration for maximum activity of soluble CPR (Frances 
et al., 2015). 
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When downscaling to microplate format (i.e. 200 µL reaction volume), several 
optimizations and control experiments were subsequently conducted. Cytochrome c 
reduction was firstly followed for 30 min at both room temperature (21 ºC) and 
physiological temperature (37 ºC), using 5 and 50 uM cytochrome c, in the presence of a 
NADPH regeneration system (200 µM NADPH, 500 µM glucose 6-phosphate and 0,04 
U/mL glucose 6-phosphate dehydrogenase, all final concentrations), to ensure constant 
and maximum reduced cofactor content during 30 min reaction time. The optimal dilution 
of samples containing CPR variants was verified by determining WT CPR activity 
measured at different CPR levels (0,5, 1, 2,5 nM) and compared with the results from the 
cuvette assay. Regarding the optimum cytochrome c concentration, a calibration curve 
was performed to ensure linearity of the reaction. After optimization of the parameters 
(i.e. temperature 37 ºC, WT CPR concentration 0,5 nM, cytochrome c concentration 100-
200 µM, buffer 100 mM Tris-HCl pH 7.4), reactions were followed for 4 min 
(measurement every 23 s). Each sample was assayed at least in triplicate (Campelo et al., 
2017). Background activity was determined by control experiments with E. coli BTC 
membranes without CPR expression, which demonstrated no cytochrome c reduction 
upon dilution (Campelo et al., 2017).  
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